Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
  • A61K31/4164—1,3-Diazoles
  • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
  • A61K31/5375—1,4-Oxazines, e.g. morpholine
  • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
  • A61P31/08—Antibacterial agents for leprosy
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/14—Antivirals for RNA viruses
  • A61P31/18—Antivirals for RNA viruses for HIV
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/12—Antivirals
  • A61P31/20—Antivirals for DNA viruses
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P35/00—Antineoplastic agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P37/00—Drugs for immunological or allergic disorders
  • A61P37/02—Immunomodulators
  • A61P37/04—Immunostimulants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
  • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
  • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
  • C07D493/10—Spiro-condensed systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
  • C07D498/18—Bridged systems
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
  • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
  • C07F9/02—Phosphorus compounds
  • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
  • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
  • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K39/00—Medicinal preparations containing antigens or antibodies
  • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
  • A61K2039/55511—Organic adjuvants
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• the present invention relates to heterocyclic amides that are useful as modulators of transmembrane protein 173 (TMEM173), which is also known as STING (Stimulator of Interferon Genes)) and methods of making and using the same.
• TMEM173 transmembrane protein 173
• STING Stimulator of Interferon Genes
• the innate immune system is the first line of defense which is initiated by Pattern Recognition Receptors (PRRs) which detect ligands from the pathogens as well as damage associated molecular patterns (Takeuchi O. et a/, Cell, 2010: 140, 805-820).
• PRRs Pattern Recognition Receptors
• TLRs Toll-like receptors
• C-type lectin receptors C-type lectin receptors
• RAG-I retinoic acid inducible gene I
• NLRs NOD-like receptors
• Activation of PRRs leads to up-regulation of genes involved in the inflammatory response including type 1 interferons, pro-inflammatory cytokines and chemokines which suppress pathogen replication and facilitate adaptive immunity.
• the adaptor protein STING (Stimulator of Interferon Genes), also known as TMEM 173, MPYS, MITA and ERIS, has been identified as a central signaling molecule in the innate immune response to cytosolic nucleic acids (Ishikawa H and Barber G N, Nature, 2008: 455, 674-678; WO2013/1666000 . Activation of STING results in up-regulation of IRF3 and NFKB pathways leading to induction of Interferon- ⁇ and other cytokines. STING is critical for responses to cytosolic DNA of pathogen or host origin, and of unusual nucleic acids called Cyclic Dinucleotides (CDNs)
• CDNs Cyclic Dinucleotides
• CDNs were first identified as bacterial secondary messengers responsible for controlling numerous responses in the prokaryotic cell.
• Bacterial CDNs, such as c-di-GMP are symmetrical molecules characterized by two 3',5' phosphodiester linkages.
• cGAMP cyclic GMP-AMP synthase
• Interferon was first described as a substance which could protect cells from viral infection (Isaacs & Lindemann, J. Virus Interference. Proc. R. Soc. Lon. Ser. B. Biol. Sci.
• interferons are a family of related proteins encoded by genes on chromosome 9 and encoding at least 13 isoforms of interferon alpha (IFNa) and one isoform of interferon beta (IFN3).
• IFNa interferon alpha
• IFN3 interferon beta
• Recombinant IFNa was the first approved biological therapeutic and has become an important therapy in viral infections and in cancer.
• interferons are known to be potent modulators of the immune response, acting on cells of the immune system.
• STING is essential for antimicrobial host defense, including protection against a range of DNA and RNA viruses and bacteria (reviewed in Barber etal. Nat. Rev. Immunol. 2015: 15(2): 87-103, Ma and Daman/a, Cell Host & Microbe, 2016: 19(2) 150-158).
• Herpesviridae, Flaviviridae, Coronaviridae, Papillomaviridae, Adenoviridae, Hepadnaviridae, ortho- and paramyxoviridae and rhabdoviridae have evolved mechanisms to inhibit STING mediated Type I interferon production and evade host immune control ⁇ Holm etal, Nat Comm.
• type I IFN production is associated with a variety of chronic infections, including Mycobacteria (Collins et al, Cell Host Microbe 2015: 17(6) 820-8); Wassermann etal, Cell Host Microbe 2015: 17(6) 799-810; Watson etal, Cell Host Microbe 2015: 17(6) 811-9), Franciscella (Storek et al, J Immunol. 2015: 194(7) 3236- 45; Jin etal, J Immunol.
• inhibitors of STING provide a treatment to patients with chronic type I interferon and proinflammatory cytokine production associated with infections or complex autoimmune diseases.
• Allergic diseases are associated with a Th2-biased immune-response to allergens.
• Th2 responses are associated with raised levels of IgE, which, via its effects on mast cells, promotes a hypersensitivity to allergens, resulting in the symptoms seen, for example, in allergic rhinitis and asthma.
• the immune-response to allergens is more balanced with a mixed Th2/Thl and regulatory T cell response.
• Type 1 interferons have been shown to result in reduction of Th2-type cytokines in the local environment and promote Thl/Treg responses.
• induction of type 1 interferons by, for example, activation of STING may offer benefit in treatment of allergic diseases such as asthma and allergic rhinitis HuberJ.P. eta/ J Immunol 2010: 185, 813-817).
• Compounds that bind to STING and act as agonist have been shown to induce type 1 interferons and other cytokines on incubation with human PBMCs.
• Compounds which induce human interferons may be useful in the treatment of various disorders, for example the treatment of allergic diseases and other inflammatory conditions for example allergic rhinitis and asthma, the treatment of infectious diseases, neurodegenerative disease, pre-cancerous syndromes and cancer, and may also be useful as immugenic composition or vaccine adjuvants.
• Compounds that bind to STING may act as antagonists and could be useful in the treatment, for example of autoimmune diseases. It is envisaged that targeting STING with activation or inhibiting agents may be a promising approach for treating diseases and conditions in which modulation for the type 1 IFN pathway is beneficial, including
• STING agonists may be used for treating viral warts, superficial skin cancers and premalignant actinic keratoses.
• STING activation e.g., via microneedle patch delivery or topical formulation
• HPV directly via antiviral type I interferon production
• STING agonist can activate the innate immune response in the lesion and drive the a nti-HPV T-cell response.
• WO2013/185052, U.S.2014/0341976, WO 2015/077354, PCT/EP2015/062281 and GB 1501462.4 disclose certain cyclic di-nucleotides and their use in inducing an immune response via activation of STING.
• the compounds of this invention modulate the activity of STING, and accordingly, may provide a beneficial therapeutic impact in treatment of diseases, disorders and/or conditions in which modulation of STING (Stimulator of Interferon Genes) is beneficial, for example for inflammation, allergic and autoimmune diseases, infectious diseases, cancer, pre-cancerous syndromes and as vaccine adjuvants.
• STING Stimulator of Interferon Genes
• the invention is directed to a compound according to Formula (I-N):
• q is 0 or 1
• r is 0 or 1;
• s is 0 or 1;
• R A1 and R A2 are each independently H, halogen, hydroxy, -0-P(0)(OH)2,
• R B1 and R B2 are each independently H, optionally substituted Ci-C6alkyl,
• halo(Ci-C6alkyl) optionally substituted C2-C6alkenyl, optionally substituted C2-C6alkynyl, optionally substituted C3-C6cycloalkyl, optionally substituted 4-6 membered
• heterocycloalkyl optionally substituted phenyl, optionally substituted 5-6 membered heteroaryl, or optionally substituted 9-10 membered heteroaryl,
• Ci-C6alkyl optionally substituted C2-C6alkenyl, optionally substituted C2-C6alkynyl, optionally substituted C3-C6cycloalkyl, optionally substituted 4-6 membered heterocycloalkyl, optionally substituted phenyl, optionally substituted 5-6 membered heteroaryl, or optionally substituted 9-10 membered heteroaryl is optionally substituted by 1-4 substituents each independently selected from halogen, nitro, -R c , -OH, -0-P(0)(OH)2, -0- -OR c , -IMH2, -NR C R C , -NR c R d , -OCOR c ,
• R C1 is H, halogen, or Ci-C4alkyl and R C2 is optionally substituted Ci-C4alkyl, wherein said optionally substituted Ci-C4alkyl group is optionally substituted by a substituent selected from -OR c , -NR c R d , -CO2R -CONR c R d , -S02NR c R d , and -OCONR c R d ; when q is 1, R A1 and R A2 are each independently -CH2-, -NR e -, or -0-, and A, taken together with R A1 and R A2 , forms a linking group, wherein A is -halo(Ci-Ci2alkyl)-, optionally substituted -Ci-Ci2alkyl-, optionally substituted -C2-Ci2alkenyl-, optionally substituted -C2-Ci2alkynyl-, optionally substitute
• R B1 and R B2 are each independently -CH2-, and B, taken together with R B1 and R B2 , forms a linking group, wherein B is a bond or B is -halo(Ci-Cioalkyl)-, optionally substituted -G-Goalkyl-, optionally substituted -C2-Cioalkenyl-, optionally substituted -C2-Cioalkynyl-, optionally substituted -Ci-C6alkyl-0-Ci-C6alkyl-, optionally substituted -Ci-C6alkyl-NR a -Ci-C6alkyl-, optionally substituted C3-C6cycloalkyl, optionally substituted phenyl, optionally substituted 4-6 membered heterocycloalkyi, optionally substituted 5-6 membered heteroaryl, optionally substituted -Ci-C4alkyl-(C3-C6cycloalkyl)-C
• -Ci-C4alkyl-phenyl-Ci-C4alkyl-, optionally substituted -Ci-C4alkyl-(4-6 membered heterocycloalkyl)-Ci-C4alkyl-, or optionally substituted -Ci-C4alkyl-(5-6 membered heteroaryl-Ci-C4alkyl)- is optionally substituted by 1 or 2 substituents each independently selected from halogen, halo(Ci-C4alkyl), -OH, -0-P(0)(OH)2, -0-P(0)(RiRii)2, -OR c , -NH 2 , -NR c R d , -OCOR c , -CO2H, -C0 2 R c , -SOR c ,
• R C1 and R C2 are each independently -CH2-, and C, taken together with R C1 and R C2 , forms a linking group, wherein C is -halo(Ci-Ci2alkyl)-, optionally substituted -Ci-Cnalkyl-, optionally substituted -C2-Ci2alkenyl-, optionally substituted -C2-Ci2alkynyl-, optionally substituted -Ci-C6alkyl-0-Ci-C6alkyl-, optionally substituted
• -Ci-C6alkyl-phenyl-Ci-C6alkyl-, optionally substituted -Ci-C6alkyl-(4-6 membered heterocycloalkyl)-Ci-C6alkyl-, or optionally substituted -Ci-C6alkyl-(5-6 membered heteroaryl)-Ci-C6alkyl- is optionally substituted by 1 or 2 substituents each independently selected from halogen, halo(Ci-C4alkyl), -OH, -0-P(0)(OH)2, -0- ⁇ (0)( ⁇ ⁇ ) 2 , -OR c , -NH2, -NR c R d , -OCOR c , -CO2H, -C0 2 R c , -SOR c , -S0 2 R c , -CONH2, -CONR c R d , -SO2NH2, -S0 2 NR c R
• R 3 and R 5 are each independently -CON(R d )(R , or one of R 3 and R 5 is -CON(R d )(R f ), and the other of R 3 and R 5 is H, COOH or -C0 2 (R c );
• R 4 and R 6 are each independently selected from H, halogen, halo(Ci-C6alkyl),
• R 14 is optionally substituted Ci-C4alkyl, wherein said optionally substituted Ci-C4alkyl is
• R 16 is H, halogen, or Ci-C4alkyl
• R 15 and R 17 are each independently H, cyclopropyl, or Ci-C4alkyl;
• R a is H, -R c , -COR c , -CO2H, -C0 2 R c , -SOR c , -SO2R -CONH2, -CONR c R d , -SO2NH2, or -S0 2 NR c R d ;
• each R b is independently Ci-C4alkyl, halo(Ci-C4alkyl), -(Ci-C4alkyl)-OH,
• each R c is independently Ci-C4alkyl, halo(Ci-C4alkyl), -(Ci-C4alkyl)-OH,
• -Ci-C4alkyl-C3-C6cycloalkyl optionally substituted -Ci-C4alkyl-phenyl, optionally substituted -G-C4alkyl-4-6 membered heterocycloalkyl, optionally substituted -Ci-C4alkyl-5-6 membered heteroaryl, or optionally substituted -Ci-C4alkyl-9-10 membered heteroaryl is optionally substituted by 1-4 substituents each independently selected from halogen, hydroxy, -0-P(0)(OH)2,
• each R d is independently H or Ci-C4alkyl
• each R e is independently H, (G-C4alkyl), -CO(Ci-C4alkyl), -OCO(G-C4alkyl), -C02(Ci-C4alkyl), -(Ci-C4alkyl)NH2, -(Ci-C4alkyl) Ci-C4alkoxy, -CO-(optionally substituted 5-6 membered heterocycloalkyl), -CO(Ci-C4alkyl)-(optionally substituted 5-6 membered
• optionally substituted 5-6 membered heterocycloalkyl or optionally substituted 5-6 membered heteroaryl is optionally substituted 1-4 substituents each independently selected from halogen, hydroxy, -0-P(0)(OH)2, amino, (G-C4alkyl)amino-, (Ci-C4alkyl)(Ci-C4alkyl)amino-, Ci-C4alkyl,
• each R f is independently H or (Ci-C4alkyl);
• R9 and R h are each independently H or (Ci-C4alkyl) or R g and R h , taken together with the atom or atoms through which they are connected, form a 5-6 membered ring;
• R 1 and R n are independently (Ci-C6alkyl)oxy-;
• references herein to compounds of Formula (I-N), (I- P) or (I), and salts thereof covers the compounds of Formula (I-N), (I-P) or (I), as free bases, or as salts thereof, for example as pharmaceutically acceptable salts thereof.
• the invention is directed to compounds of Formula (I-N), (I-P) or (I), as the free base.
• the invention is directed to compounds of Formula (I-N), (I-P) or (I), and salts thereof.
• the invention is directed to compounds of Formula (I-N), (I-P) or (I), and pharmaceutically acceptable salts thereof.
• the compounds according to Formula (I-N), (I-P) or (I), or salts, particularly pharmaceutically acceptable salts, thereof, are modulators of STING. Accordingly, this invention provides a compound of Formula (I-N), (I-P) or (I) or a salt thereof, particularly a pharmaceutically acceptable salt thereof, for use in therapy.
• This invention specifically provides for the use of a compound of Formula (I-N), (I-P) or (I), or a pharmaceutically acceptable salt thereof, as an active therapeutic substance in the treatment of a STING- mediated disease or disorder, specifically, for use in the treatment of a disease mediated by agonism or antagonism of STING.
• the invention also provides a compound of Formula (I- N), (I-P) or (I), or a salt thereof, particularly a pharmaceutically acceptable salt thereof, for use in the manufacture of a medicament for the treatment of a STING-mediated disease or disorder.
• the invention is also directed to a method of modulating STING, which method comprises contacting a cell with a compound according to Formula (I-N), (I-P) or (I), or a salt, particularly a pharmaceutically acceptable salt, thereof.
• the invention is further directed to a method of treating a STING-mediated disease or disorder which comprises administering a therapeutically effective amount of a compound according to Formula (I-N), (I-P) or (I), or a salt, particularly a pharmaceutically acceptable salt thereof, to a patient (a human or other mammal, particularly, a human) in need thereof.
• STING-mediated diseases or disorders include inflammation, allergic and autoimmune diseases, infectious diseases, cancer, and pre-cancerous syndromes.
• modulators of STING may be useful as immugenic composition or vaccine adjuvants.
• the present invention is further directed to a pharmaceutical composition
• a pharmaceutical composition comprising a compound according to Formula (I-N), (I-P) or (I), or a salt, particularly a pharmaceutically acceptable salt, thereof and a pharmaceutically acceptable excipient.
• this invention is directed to a pharmaceutical composition for the treatment of a STING-mediated disease or disorder, where the composition comprises a compound according to Formula (I- N), (I-P) or (I), or a salt, particularly a pharmaceutically acceptable salt, thereof and a pharmaceutically acceptable excipient.
• this invention relates to compounds of Formula (I-N)
• q is 0 or 1
• r is O or l
• s is 0 or 1;
• R A1 and R A2 are each independently H, halogen, hydroxy, -0-P(0)(OH)2,
• R B1 and R B2 are each independently H, optionally substituted Ci-C6alkyl,
• halo(Ci-C6alkyl) optionally substituted C 2 -C6alkenyl, optionally substituted C 2 -C6alkynyl, optionally substituted C3-C6cycloalkyl, optionally substituted 4-6 membered
• heterocycloalkyl optionally substituted phenyl, optionally substituted 5-6 membered heteroaryl, or optionally substituted 9-10 membered heteroaryl,
• Ci-C6alkyl optionally substituted C 2 -C6alkenyl, optionally substituted C 2 -C6alkynyl, optionally substituted C3-C6cycloalkyl, optionally substituted 4-6 membered heterocycloalkyl, optionally substituted phenyl, optionally substituted 5-6 membered heteroaryl, or optionally substituted 9-10 membered heteroaryl is optionally substituted by 1-4 substituents each independently selected from halogen, nitro, -R c , -OH, -0-P(0)(OH) 2 , -0- ⁇ (0)( ⁇ ⁇ ) 2 , -OR c , -NH 2 , -NR C R C , -NR c R d , -OCORS -C0 2 H, -C0 2 R c , -SOR c , -S0 2 R c , -CONH 2 , -CONR c R
• -Ci-C6alkyl-phenyl-Ci-C6alkyl-, optionally substituted -Ci-C6alkyl-(4-6 membered heterocycloalkyl)-Ci-C6alkyl-, or optionally substituted -Ci-C6alkyl-(5-6 membered heteroaryl)-Ci-C6alkyl- is optionally substituted by 1-4 substituents each independently selected from halogen, halo(Ci-C4alkyl), -OH, -0-P(0)(OH)2, -0-P(0)(R I R II )2, -OR c , -NH 2 , -NR c R d , -OCOR c , -CO2H, -CO2R -SOR c ,
• R B1 and R B2 are each independently -CH2-, and B, taken together with R B1 and R B2 , forms a linking group, wherein B is a bond or B is -halo(Ci-Cioalkyl)-, optionally substituted -Ci-Cioalkyl-, optionally substituted -C2-Cioalkenyl-, optionally substituted -C2-Cioalkynyl-, optionally substituted -Ci-C6alkyl-0-Ci-C6alkyl-, optionally substituted -Ci-C6alkyl-NR a -Ci-C6alkyl-, optionally substituted C3-C6cycloalkyl, optionally substituted phenyl, optionally substituted 4-6 membered heterocycloalkyi, optionally substituted 5-6 membered heteroaryl, optionally substituted -Ci-C4alkyl-(C3-C6cycloalkyl)
• -Ci-C4alkyl-phenyl-Ci-C4alkyl-, optionally substituted -Ci-C4alkyl-(4-6 membered heterocycloalkyl)-Ci-C4alkyl-, or optionally substituted -Ci-C4alkyl-(5-6 membered heteroaryl-Ci-C4alkyl)- is optionally substituted by 1 or 2 substituents each independently selected from halogen, halo(Ci-C4alkyl), -OH, -0-P(0)(OH)2, -OR c , -IMH2, -NR c R d , -OCOR c , -CO2H, -C0 2 R c , -SOR c , -SO2R -CONH2, -CONR c R d , -SO2NH2, -S0 2 NR c R d , -OCONH2, -OCONR c R
• R C1 and R C2 are each independently -CH2-, and C, taken together with R C1 and R C2 , forms a linking group, wherein C is -halo(Ci-Ci2alkyl)-, optionally substituted -Ci-Cnalkyl-, optionally substituted -C2-Ci2alkenyl-, optionally substituted -C2-Ci2alkynyl-, optionally substituted -Ci-C6alkyl-0-Ci-C6alkyl-, optionally substituted
• -Ci-C6alkyl-phenyl-Ci-C6alkyl-, optionally substituted -Ci-C6alkyl-(4-6 membered heterocycloalkyl)-Ci-C6alkyl-, or optionally substituted -Ci-C6alkyl-(5-6 membered heteroaryl)-Ci-C6alkyl- is optionally substituted by 1 or 2 substituents each independently selected from halogen, halo(Ci-C4alkyl), -OH, -0-P(0)(OH)2, -OR c , -NH 2 , -NR c R d , -OCOR c , -CO2H, -C0 2 R c , -SOR c , -S0 2 R c , -CONH2, -CONR c R d , -SO2NH2, -S0 2 NR c R d , -OCONH2, -
• R 3 and R 5 are each independently -CON(R d )(R , or one of R 3 and R 5 is -CON(R d )(R f ), and the other of R 3 and R 5 is H, COOH or -C0 2 (R c );
• R 4 and R 6 are each independently selected from H, halogen, halo(Ci-C6alkyl),
• R 14 is optionally substituted Ci-C4alkyl, wherein said optionally substituted Ci-C4alkyl is
• R 16 is H, halogen, or Ci-C4alkyl
• R 15 and R 17 are each independently H, cyclopropyl, or Ci-C4alkyl;
• R a is H, -R c , -COR c , -CO2H, -C0 2 R c , -SOR c , -SO2R -CONH2, -CONR c R d , -SO2NH2,
• each R b is independently Ci-C4alkyl, halo(Ci-C4alkyl), -(Ci-C4alkyl)-OH,
• each R c is independently Ci-C4alkyl, halo(Ci-C4alkyl), -(Ci-C4alkyl)-OH,
• -Ci-C4alkyl-4-6 membered heterocycloalkyl optionally substituted -Ci-C4alkyl-5-6 membered heteroaryl, or optionally substituted -Ci-C4alkyl-9-10 membered heteroaryl, wherein the C3-C6cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl or 9-10 membered heteroaryl moiety of said optionally substituted C3-C6cycloalkyl, optionally substituted phenyl, optionally substituted 4-6 membered heterocycloalkyl, optionally substituted 5-6 membered heteroaryl, optionally substituted 9-10 membered heteroaryl optionally substituted -Ci-C4alkyl-C3-C6cycloalkyl, optionally substituted -Ci-C4alkyl-phenyl, optionally substituted -Ci-C4alkyl-4-6 membered heterocycloalky
• each R e is independently H, (Ci-C4alkyl), -CO(Ci-C4alkyl), -OCO(G-C4alkyl), -C02(Ci-C4alkyl), -(Ci-C4alkyl)NH2, -(Ci-C4alkyl) Ci-C4alkoxy, -CO-(optionally substituted 5-6 membered heterocycloalkyl), -CO(Ci-C4alkyl)-(optionally substituted 5-6 membered
• optionally substituted 5-6 membered heterocycloalkyl or optionally substituted 5-6 membered heteroaryl is optionally substituted 1-4 substituents each independently selected from halogen, hydroxy, -0-P(0)(OH) 2 ,
• each R f is independently H or (Ci-C4alkyl);
• R9 and R h are each independently H or (Ci-C4alkyl) or R g and R h , taken together with the atom or atoms through which they are connected, form a 5-6 membered ring;
• R 1 and R n are independently (Ci-C6alkyl)oxy-;
• the invention is directed to a compound according to Formula (I-P):
• q is 0 or 1
• r is 0 or 1;
• s is 0 or 1;
• R A1 and R A2 are each independently H, halogen, hydroxy, -0-P(0)(OH)2,
• R B1 and R B2 are each independently H, optionally substituted Ci-C6alkyl,
• halo(Ci-C6alkyl) optionally substituted C2-C6alkenyl, optionally substituted C2-C6alkynyl, optionally substituted C3-C6cycloalkyl, optionally substituted 4-6 membered
• heterocycloalkyl optionally substituted phenyl, optionally substituted 5-6 membered heteroaryl, or optionally substituted 9-10 membered heteroaryl,
• Ci-C6alkyl, optionally substituted C2-C6alkenyl, optionally substituted C2-C6alkynyl, optionally substituted C3-C6cycloalkyl, optionally substituted 4-6 membered heterocycloalkyl, optionally substituted phenyl, optionally substituted 5-6 membered heteroaryl, or optionally substituted 9-10 membered heteroaryl is optionally substituted by 1-4 substituents each independently selected from halogen, nitro, -R c , -OH, -0-P(0)(OH) 2 , -0- ⁇ (0)( ⁇ ⁇ ) 2 , -OR c , -NH 2 , -NR C R C , -NR c R d , -OCOR -CO2H, -C0 2 R c , -SOR c , -SO2R -CONH2, -CONR c R d , -SO2NH2, -SO
• -Ci-C6alkyl-phenyl-Ci-C6alkyl-, optionally substituted -Ci-C6alkyl-(4-6 membered heterocycloalkyl)-Ci-C6alkyl-, or optionally substituted -Ci-C6alkyl-(5-6 membered heteroaryl)-Ci-C6alkyl- is optionally substituted by 1-4 substituents each independently selected from halogen, halo(Ci-C4alkyl), -OH, -0-P(0)(OH)2, -OR c , -NH 2 , -NR c R d , -OCOR c , -CO2H, -C0 2 R c , -SOR c , -SO2R -CONH2, -CONR c R d , -SO2NH2, -S0 2 NR c R d , -OCONH2, -OCONR c R
• R B1 and R B2 are each independently -CH2-, and B, taken together with R B1 and R B2 , forms a linking group, wherein B is a bond or B is -halo(Ci-Cioalkyl)-, optionally substituted -G-Goalkyl-, optionally substituted -C2-Cioalkenyl-, optionally substituted -C2-Cioalkynyl-, optionally substituted -Ci-C6alkyl-0-Ci-C6alkyl-, optionally substituted -Ci-C6alkyl-NR a -Ci-C6alkyl-, optionally substituted C3-C6cycloalkyl, optionally substituted phenyl, optionally substituted 4-6 membered heterocycloalkyi, optionally substituted 5-6 membered heteroaryl, optionally substituted -Ci-C4alkyl-(C3-C6cycloalkyl)-C
• -G-Gialkyl-phenyl-Ci-Gialkyl-, optionally substituted -G-C4alkyl-(4-6 membered heterocycloalkyl)-Ci-C4alkyl-, or optionally substituted -G-C4alkyl-(5-6 membered heteroaryl-Ci-C4alkyl)- is optionally substituted by 1 or 2 substituents each independently selected from halogen, halo(Ci-C4alkyl), -OH, -0-P(0)(OH)2, -0-P(0)(RiRii) 2 , -OR c , -NH 2 , -NR c R d , -OCOR c , -CO2H, -C0 2 R c ,
• R C1 and R C2 are each independently -CH2-, and C, taken together with R C1 and R C2 , forms a linking group, wherein C is -halo(Ci-Ci2alkyl)-, optionally substituted -Ci-Cnalkyl-, optionally substituted -C2-Ci2alkenyl-, optionally substituted -C2-Ci2alkynyl-, optionally substituted -Ci-C6alkyl-0-Ci-C6alkyl-, optionally substituted
• -Ci-C6alkyl-phenyl-Ci-C6alkyl-, optionally substituted -Ci-C6alkyl-(4-6 membered heterocycloalkyl)-Ci-C6alkyl-, or optionally substituted -Ci-C6alkyl-(5-6 membered heteroaryl)-Ci-C6alkyl- is optionally substituted by 1 or 2 substituents each independently selected from halogen, halo(Ci-C4alkyl), -OH, -0-P(0)(OH)2, -0- ⁇ (0)( ⁇ *3 ⁇ 4 ⁇ )2, -OR c , -NH 2 , -NR c R d , -OCOR c , -CO2H, -C0 2 R c , -SOR c ,
• R 3 and R 5 are each independently -CON(R d )(R , or one of R 3 and R 5 is -CON(R d )(R f ), and the other of R 3 and R 5 is H, COOH or -C0 2 (R c );
• R 4 and R 6 are each independently selected from H, halogen, halo(Ci-C6alkyl),
• Ci-C4alkyl (Ci-C4alkyl)amino-, Ci-C4alkyl, halo(Ci-C4alkyl), hydroxy-(Ci-C4alkyl)-, -(Ci-C4alkyl)-0-P(0)(OH) 2 , -(Ci-C4alkyl)-0-P(0)(R I R II )2, halo(Ci-C4alkoxy)-, Ci-C4alkoxy-, hydroxy-(C2-C4alkoxy)-, -(C2-C4alkoxy)-0-P(0)(OH)2, -(C2-C4alkoxy)- Ci-C4alkoxy-(Ci-C4alkoxy)-, -COR d , -CON(R d )(R , and -C0 2 R d ; R 14 is optionally substituted Ci-C4alkyl, wherein said optionally substituted Ci-C4alkyl
• R 16 is H, halogen, or Ci-C4alkyl
• R 15 and R 17 are each independently H, cyclopropyl, or Ci-C4alkyl;
• R a is H, -R c , -COR c , -CO2H, -C0 2 R c , -SOR c , -SO2R -CONH2, -CONR c R d , -SO2NH2,
• each R b is independently Ci-C4alkyl, halo(Ci-C4alkyl), -(Ci-C4alkyl)-OH,
• each R c is independently Ci-C4alkyl, halo(Ci-C4alkyl), -(Ci-C4alkyl)-OH,
• -Ci-C4alkyl-4-6 membered heterocycloalkyl optionally substituted -Ci-C4alkyl-5-6 membered heteroaryl, or optionally substituted -Ci-C4alkyl-9-10 membered heteroaryl, wherein the C3-C6cycloalkyl, phenyl, 4-6 membered heterocycloalkyl, 5-6 membered heteroaryl or 9-10 membered heteroaryl moiety of said optionally substituted C3-C6cycloalkyl, optionally substituted phenyl, optionally substituted 4-6 membered heterocycloalkyl, optionally substituted 5-6 membered heteroaryl, optionally substituted 9-10 membered heteroaryl optionally substituted
• -Ci-C4alkyl-C3-C6cycloalkyl optionally substituted -Ci-C4alkyl-phenyl, optionally substituted -G-C4alkyl-4-6 membered heterocycloalkyl, optionally substituted -Ci-C4alkyl-5-6 membered heteroaryl, or optionally substituted -Ci-C4alkyl-9-10 membered heteroaryl is optionally substituted by 1-4 substituents each independently selected from halogen, hydroxy, -0-P(0)(OH)2, amino, -(Ci-dalkyl)NH 2 , (Ci-C4alkyl)amino-, (Ci-C4alkyl)(Ci-C4alkyl)amino-, Ci-C4alkyl, halo(Ci-C4alkyl), halo(Ci-C4alkoxy)-, Ci-C4alkoxy-, hydroxy-(C2-C4alk
• each R d is independently H or Ci-C4alkyl
• each R e is independently H, (Ci-C4alkyl), -CO(Ci-C4alkyl), -OCO(G-C4alkyl), -C02(Ci-C4alkyl), -(Ci-C4alkyl)NH2, -(Ci-C4alkyl) Ci-C4alkoxy, -CO-(optionally substituted 5-6 membered heterocycloalkyl), -CO(Ci-C4alkyl)-(optionally substituted 5-6 membered
• optionally substituted 5-6 membered heterocycloalkyl or optionally substituted 5-6 membered heteroaryl is optionally substituted 1-4 substituents each independently selected from halogen, hydroxy, -0-P(0)(OH) 2 ,
• each R f is independently H or (Ci-C4alkyl);
• R 9 and R h are each independently H or (Ci-C4alkyl) or R 9 and R h , taken together with the atom or atoms through which they are connected, form a 5-6 membered ring;
• R 1 and R n are independently (Ci-C6alkyl)oxy-;
• Another aspect of the present invention is directed to compounds of Formula (I)
• q is 0 or 1
• r is 0 or 1;
• s is 0 or 1;
• R A1 and R A2 are each independently H, halogen, hydroxy, -N(R e )(R ,
• R B1 and R B2 are each independently H, optionally substituted Ci-C6alkyl,
• halo(Ci-C6alkyl) optionally substituted C2-C6alkenyl, optionally substituted C2-C6alkynyl, optionally substituted C3-C6cycloalkyl, optionally substituted 4-6 membered
• heterocycloalkyl optionally substituted phenyl, optionally substituted 5-6 membered heteroaryl, or optionally substituted 9-10 membered heteroaryl,
• Ci-Cealkyl optionally substituted C2-C6alkenyl, optionally substituted C2-C6alkynyl, optionally substituted C3-C6cycloalkyl, optionally substituted 4-6 membered heterocycloalkyl, optionally substituted phenyl, optionally substituted 5-6 membered heteroaryl, or optionally substituted 9-10 membered heteroaryl is optionally substituted by 1-4 substituents each independently selected from halogen,
• R C1 is H, halogen, or Ci-C4alkyl and R C2 is optionally substituted Ci-C4alkyl, wherein said optionally substituted Ci-C4alkyl group is optionally substituted by a substituent selected from -OR c , -NR c R d , -CO2R -CONR c R d , -S02NR c R d , and -OCONR c R d ; when q is 1, R A1 and R A2 are each independently -CH2-, -NR e -, or -0-, and A, taken together with R A1 and R A2 , forms a linking group, wherein A is -halo(Ci-Ci2alkyl)-, optionally substituted -G-Ci2alkyl-, optionally substituted -C2-Ci2alkenyl-, optionally substituted -C2-Ci2alkynyl-, optionally substituted
• -Ci-C6alkyl-phenyl-Ci-C6alkyl-, optionally substituted -Ci-C6alkyl-(4-6 membered heterocycloalkyl)-Ci-C6alkyl-, or optionally substituted -Ci-C6alkyl-(5-6 membered heteroaryl)-Ci-C6alkyl- is optionally substituted by 1-4 substituents each independently selected from halogen, halo(Ci-C4alkyl), -OH, -OR c , -IMH2, -NR c R d , -OCOR c , -CO2H, -C0 2 R c , -SOR c , -SO2R -CONH2, -CONR c R d , -SO2NH2, -S0 2 NR c R d , -0 CONH2, -OCONR c R d , -NR d C
• -Ci-C6alkyl-phenyl-Ci-C6alkyl-, optionally substituted -Ci-C6alkyl-(4-6 membered heterocycloalkyl)-Ci-C6alkyl-, or optionally substituted -Ci-C6alkyl-(5-6 membered heteroaryl)-Ci-C6alkyl- is optionally substituted by 1-4 substituents each independently selected from halogen, hydroxy, amino, (G-C4alkyl)amino-, (Ci-C4alkyl)(Ci-C4alkyl)amino-, Ci-C4alkyl, halo(Ci-C4alkyl), halo(Ci-C4alkoxy)-, Ci-C4alkoxy-, hydroxy-(C2-C4alkoxy)-, and Ci-C4alkoxy-(Ci-C4alkoxy)-;
• R B1 and R B2 are each independently -CH2-, and B, taken together with R B1 and R B2 , forms a linking group, wherein B is a bond or B is -halo(Ci-Cioalkyl)-, optionally substituted -G-Goalkyl-, optionally substituted -C2-Cioalkenyl-, optionally substituted -C2-Cioalkynyl-, optionally substituted -Ci-C6alkyl-0-Ci-C6alkyl-, optionally substituted -Ci-C6alkyl-NR a -Ci-C6alkyl-, optionally substituted C3-C6cycloalkyl, optionally substituted phenyl, optionally substituted 4-6 membered heterocycloalkyi, optionally substituted 5-6 membered heteroaryl, optionally substituted -Ci-C4alkyl-(C3-C6cycloalkyl)-C
• -Ci-C4alkyl-phenyl-Ci-C4alkyl-, optionally substituted -Ci-C4alkyl-(4-6 membered heterocycloalkyl)-Ci-C4alkyl-, or optionally substituted -Ci-C4alkyl-(5-6 membered heteroaryl-Ci-C4alkyl)- is optionally substituted by 1 or 2 substituents each independently selected from halogen,
• -Ci-C4alkyl-phenyl-Ci-C4alkyl-, optionally substituted -Ci-C4alkyl-(4-6 membered heterocycloalkyl)-Ci-C4alkyl-, or optionally substituted -Ci-C4alkyl-(5-6 membered heteroaryl)-Ci-C4alkyl- is optionally substituted by 1-4 substituents each independently selected from halogen, hydroxy, amino, (Ci-C4alkyl)amino-, (Ci-C4alkyl)(Ci-C4alkyl)amino-, Ci-C4alkyl, halo(Ci-C4alkyl), halo(Ci-C4alkoxy)-, Ci-C4alkoxy-, hydroxy-(C2-C4alkoxy)-, and Ci-C4alkoxy-(Ci-C4alkoxy)-;
• R C1 and R C2 are each independently -CH2-, and C, taken together with R C1 and R C2 , forms a linking group, wherein C is -halo(Ci-Ci2alkyl)-, optionally substituted -Ci-Cnalkyl-, optionally substituted -C2-Ci2alkenyl-, optionally substituted -C2-Ci2alkynyl-, optionally substituted -Ci-C6alkyl-0-Ci-C6alkyl-, optionally substituted
• -Ci-C6alkyl-phenyl-Ci-C6alkyl-, optionally substituted -Ci-C6alkyl-(4-6 membered heterocycloalkyl)-Ci-C6alkyl-, or optionally substituted -Ci-C6alkyl-(5-6 membered heteroaryl)-Ci-C6alkyl- is optionally substituted by 1 or 2 substituents each independently selected from halogen, halo(Ci-C4alkyl), -OH, -OR c , -IMH2, -NR c R d , -OCOR c , -CO2H, -C0 2 R c , -SOR c , -S0 2 R c , -CONH2, -CONR c R d , -SO2NH2, -S0 2 NR c R d , -OCONH2, -OCONR c R d ,
• Ci-C4alkyl (Ci-C4alkyl)amino-, Ci-C4alkyl, halo(Ci-C4alkyl), halo(Ci-C4alkoxy)-, Ci-C4alkoxy-, hydroxy-(C2-C4alkoxy)-, and Ci-C4alkoxy-(Ci-C4alkoxy)-;
• R 3 and R 5 are each independently -CON(R d )(R , or one of R 3 and R 5 is -CON(R d )(R f ), and the other of R 3 and R 5 is H or -C02(R C );
• R 4 and R 6 are each independently selected from H, halogen, halo(Ci-C6alkyl),
• R 14 is optionally substituted Ci-C4alkyl, wherein said optionally substituted Ci-C4alkyl is
• R 16 is H, halogen, or Ci-C4alkyl
• R 15 and R 17 are each independently H, cyclopropyl, or Ci-C4alkyl;
• R a is H, -R c , -COR c , -CO2H, -C0 2 R c , -SOR c , -SO2R -CONH2, -CONR c R d , -SO2NH2,
• each R b is independently Ci-C4alkyl
• each R c is independently Ci-C4alkyl
• -Ci-C4alkyl-C3-C6cycloalkyl optionally substituted -Ci-C4alkyl-phenyl, optionally substituted -Ci-C 4 alkyl-4-6 membered heterocycloalkyl, optionally substituted -Ci-C 4 alkyl-5-6 membered heteroaryl, or optionally substituted -Ci-C 4 alkyl-9-10 membered heteroaryl is optionally substituted by 1-4 substituents each independently selected from halogen, hydroxy, amino, (Ci-C4alkyl)amino-, (Ci-C4alkyl)(Ci-C4alkyl)amino-, Ci-C 4 alkyl, halo(Ci-C 4 alkyl), halo(Ci-C4alkoxy)-, Ci-C4alkoxy-, hydroxy-(C2-C4alkoxy)-, Ci-C4alkoxy-(Ci-C4alkoxy)-
• each R d is independently H or Ci-C 4 alkyl
• each R e is independently H, (Ci-C 4 alkyl), -CO(Ci-C4alkyl), -OCO(Ci-C4alkyl), -C02(Ci-C4alkyl), -CO-(optionally substituted 5-6 membered heterocycloalkyl), -CO(Ci-C4alkyl)-(optionally substituted 5-6 membered heterocycloalkyl), -CO(optionally substituted 5-6 membered heteroaryl), -CO(Ci-C4alkyl)-(optionally substituted 5-6 membered heteroaryl),
• optionally substituted 5-6 membered heterocycloalkyl or optionally substituted 5-6 membered heteroaryl is optionally substituted 1-4 substituents each independently selected from halogen, hydroxy, amino, (Ci-C4alkyl)amino-, (Ci-C4alkyl)(Ci-C4alkyl)amino-, Ci-C 4 alkyl, halo(Ci-C 4 alkyl), halo(Ci-C4alkoxy)-, Ci-C4alkoxy-, hydroxy-(C2-C4alkoxy)-, G-C4alkoxy-(Ci-C4alkoxy)- , -COR d , -CON(R d )(R f ), and -C0 2 R d ;
• each R f is independently H or (Ci-C4alkyl);
• R9 and R h are each independently H or (Ci-C4alkyl) or R g and R h , taken together with the atom or atoms through which they are connected, form a 5-6 membered ring;
• any reference to a named compound (an intermediate compound or a compound of the invention) or a structurally depicted compound (an intermediate compound or a compound of the invention) is intended to encompass all tautomeric forms including zwitterionic forms of such compounds and any mixture thereof.
• alkyl represents a saturated, straight or branched hydrocarbon group having the specified number of carbon atoms.
• Ci-C4alkyl refers to a straight or branched alkyl moiety containing from 1 to 4 carbon atoms.
• Exemplary alkyls include, but are not limited to methyl, ethyl, />propyl, isopropyl, /7-butyl, isobutyl, s-butyl, t- butyl, pentyl and hexyl.
• hydroxy(G-C4alkyl) When a substituent term such as “alkyl” is used in combination with another substituent term, for example as in “hydroxy(G-C4alkyl)", the linking substituent term (e.g., alkyl) is intended to encompass a divalent moiety, wherein the point of attachment is through that linking substituent.
• substituent term such as “alkyl”
• alkyl is intended to encompass a divalent moiety, wherein the point of attachment is through that linking substituent.
• hydroxy(G-C4alkyl) groups include, but are not limited to, hydroxy methyl, hydroxyethyl, and hydroxyisopropyl.
• halo(alkyl) represents a saturated, straight or branched hydrocarbon group having the specified number (n) of carbon atoms and one or more (up to 2n+l) halogen atoms.
• halo(Ci-C4alkyl) represents a group having one or more halogen atoms, which may be the same or different, at one or more carbon atoms of an alkyl moiety containing from 1 to 4 carbon atoms.
• halo(Ci-C4alkyl) groups include, but are not limited to, -CF3 (trifluoromethyl), -CCI3 (trichloromethyl), 1,1- difluoroethyl, 2,2,2-trifluoroethyl, and hexafluoroisopropyl.
• Alkenyl refers to straight or branched hydrocarbon group having the specified number of carbon atoms and at least 1 and up to 3 carbon-carbon double bonds. Examples include ethenyl and propenyl.
• Alkynyl refers to straight or branched hydrocarbon group having the specified number of carbon atoms and at least 1 and up to 3 carbon-carbon triple bonds. Examples include ethynyl and propynyl.
• Alkoxy- or "(alkyl)oxy-” refers to an "alkyl-oxy-" group, containing an alkyl moiety, having the specified number of carbon atoms, attached through an oxygen linking atom.
• the term "Ci-C4alkoxy-” represents a saturated, straight or branched hydrocarbon moiety having at least 1 and up to 4 carbon atoms attached through an oxygen linking atom.
• Exemplary "Ci-C4alkoxy-" or “(Ci-C4alkyl)oxy-” groups include, but are not limited to, methoxy, ethoxy, />propoxy, isopropoxy, /7-butoxy, s-butoxy, and f-butoxy.
• halo(alkoxy)- represents a saturated, straight or branched hydrocarbon group having the specified number (n) of carbon atoms and one or more (up to 2n+l) halogen atoms, attached through an oxygen linking atom.
• halo(Ci-C4alkoxy)- refers to a "haloalkyl-oxy-” group, containing a "halo(Ci-C4alkyl)” moiety attached through an oxygen linking atom.
• Exemplary "halo(Ci-C4alkoxy)-” groups include, but are not limited to, -OCHF2 (difluoromethoxy), -OCF3 (trifluoromethoxy), -OCH2CF3
• a carbocyclic group or moiety is a cyclic group or moiety in which the ring members are carbon atoms, which may be saturated, partially unsaturated (non-aromatic) or fully unsaturated (aromatic).
• Cycloalkyl refers to a non-aromatic, saturated, hydrocarbon ring group containing the specified number of carbon atoms in the ring.
• C3-C6cycloalkyl refers to a cyclic group having from three to six ring carbon atoms.
• Exemplary "C3-C6cycloalkyl” groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
• a heterocyclic group or moiety is a cyclic group or moiety having, as ring members, atoms of at least two different elements, which cyclic group or moiety may be saturated, partially unsaturated (non-aromatic) or fully unsaturated (aromatic).
• Heteroatom refers to a nitrogen, sulfur, or oxygen atom, for example a nitrogen atom or an oxygen atom.
• Heterocycloalkyl refers to a non-aromatic, monocyclic or bicyclic group containing 3-10 ring atoms and containing one or more (generally one or two) heteroatom ring members independently selected from oxygen, sulfur, and nitrogen.
• the point of attachment of a heterocycloalkyl group may be by any suitable carbon or nitrogen atom.
• heterocycloalkyl groups include, but are not limited to, aziridinyl, thiiranyl, oxiranyl, azetidinyl, oxetanyl, thietanyl, pyrrolidinyl, tetrahydrofuranyl,
• tetrahydrothienyl 1,3-dioxolanyl, piperidinyl, piperazinyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, 1,3-dioxanyl, 1,4-dioxanyl, 1,3-oxathiolanyl, 1,3-oxathianyl, 1,3- dithianyl, 1,4-oxathiolanyl, 1,4-oxathianyl, 1,4-dithianyl, morpholinyl, thiomorpholinyl, and hexahydro-l l,4-diazepinyl.
• Examples of "4-membered heterocycloalkyl” groups include oxetanyl, thietanyl and azetidinyl.
• 5-6 membered heterocycloalkyl represents a saturated, monocyclic group, containing 5 or 6 ring atoms, which includes one or two heteroatoms selected independently from oxygen, sulfur, and nitrogen.
• Illustrative examples of 5-6 membered heterocycloalkyl groups include, but are not limited to pyrrolidinyl, tetrahydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, tetrahydrothiopyranyl, piperidinyl, piperazinyl, morpholinyl, and thiomorpholinyl.
• Heteroaryl refers to an aromatic monocyclic or bicyclic group containing 5 to 10 ring atoms, including 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur, wherein at least a portion of the group is aromatic.
• this term encompasses bicyclic heterocyclic-aryl groups containing either a phenyl ring fused to a heterocyclic moiety or a heteroaryl ring moiety fused to a carbocyclic moiety.
• the point of attachment of a heteroaryl group may be by any suitable carbon or nitrogen atom.
• 5-6 membered heteroaryl represents an aromatic monocyclic group containing 5 or 6 ring atoms, including at least one carbon atom and 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur.
• Selected 5-membered heteroaryl groups contain one nitrogen, oxygen, or sulfur ring heteroatom, and optionally contain 1, 2, or 3 additional nitrogen ring atoms.
• Selected 6-membered heteroaryl groups contain 1, 2, or 3 nitrogen ring heteroatoms.
• 5-membered heteroaryl groups include furyl (furanyl), thienyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, thiazolyl, isothiazolyl, thiadiazolyl, oxazolyl, isoxazolyl, and oxadiazolyl.
• Selected 6-membered heteroaryl groups include pyridinyl (pyridyl), pyrazinyl, pyrimidinyl, pyridazinyl and triazinyl.
• 9-10 membered heteroaryl refers to an aromatic bicyclic group containing 9 or 10 ring atoms, including 1 to 4 heteroatoms independently selected from nitrogen, oxygen and sulfur.
• 9-membered heteroaryl (6,5-fused heteroaryl) groups include benzothienyl, benzofuranyl, indolyl, indolinyl (dihydroindolyl), isoindolyl, isoindolinyl, indazolyl, isobenzofuryl, 2,3-dihydrobenzofuryl, benzoxazolyl, benzoisoxazolyl, benzothiazolyl, benzoisothiazolyl, benzimidazolyl, benzoxadiazolyl, benzothiadiazolyl, benzotriazolyl, purinyl, imidazopyridinyl, pyrazolopyridinyl, triazolopyridinyl and 1,3-benzodioxolyl.
• 10-membered heteroaryl (6,6-fused heteroaryl) groups include quinolinyl (quinolyl), isoquinolyl, phthalazinyl, naphthridinyl (1,5-naphthyridinyl, 1,6-naphthyridinyl, 1,7- naphthyridinyl, 1,8-naphthyridinyl), quinazolinyl, quinoxalinyl, 4H-quinolizinyl, 1,2,3,4- tetrahydroquinolinyl (tetrahydroquinolinyl), 1,2,3,4-tetrahydroisoquinolinyl
• halogen and halo refers to a halogen radical, for example, a fluoro, chloro, bromo, or iodo substituent.
• cyano refers to a nitrile group, -C ⁇ N.
• the term "optionally substituted” indicates that a group (such as an alkyl, cycloalkyl, alkoxy, heterocycloalkyl, aryl, or heteroaryl group) or ring or moiety may be unsubstituted, or the group, ring or moiety may be substituted with one or more substituent(s) as defined in the substituent definitions (A, R 3 , etc,) provided herein.
• groups may be selected from a number of alternative groups, the selected groups may be the same or different.
• pharmaceutically acceptable refers to those compounds, materials, compositions, and dosage forms which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, or other problem or complication, commensurate with a reasonable benefit/risk ratio.
• the terms "compound(s) of the invention” or “compound(s) of this invention” mean a compound of Formula (I-N), Formula (I) or Formula (I-P), as defined herein, in any form, i.e., any tautomeric form, any isomeric form, any salt or non-salt form (e.g., as a free acid or base form, or as a salt, particularly a pharmaceutically acceptable salt thereof) and any physical form thereof (e.g., including non-solid forms (e.g., liquid or semi-solid forms), and solid forms (e.g., amorphous or crystalline forms, specific polymorphic forms, solvate forms, including hydrate forms (e.g., mono-, di- and hemi- hydrates)), and mixtures of various forms.
• any form i.e., any tautomeric form, any isomeric form, any salt or non-salt form (e.g., as a free acid or base form, or as a salt, particularly
• R 3 and R 5 are each independently -CON(R d )(R f ), or one of R 3 and R 5 is -CON(R d )(R f ), and the other of R 3 and R 5 is H or -C02(R C ).
• R 3 and R 5 are each independently -CON(R d )(R . In another embodiment, one of R 3 and R 5 is -CON(R d )(R f ) and the other of R 3 and R 5 is H. In a specific embodiment, R 3 and R 5 are each -CONH2.
• q is 1, r is 0 and s is 0
• R A1 and R A2 are each independently H, halogen, hydroxy, -N(R e )(R , -C02R f , -N(R COR b ,
• R A1 and R A2 are each independently H, halogen, hydroxy, -0-P(0)(OH) 2 , -N(R e )(R f ), -C0 2 R f , -N(R f )COR b , -N(R 9 )SO 2 (Ci-C4alkyl)-N(R e )(R , -N(R 9 )CO(Ci-C4alkyl)-N(R h )(R f ), optionally substituted (Ci-C6alkyl), optionally substituted (Ci-C6alkyl)oxy-, optionally substituted (G-C6alkyl)amino-, and optionally substituted (Ci-C6alkyl)(Ci-C4alkyl)amino-, wherein the (Ci-Cealkyl) of said optionally substituted (Ci-C6
• R A1 and R A2 are each independently H, hydroxy, amino, (G-C4alkyl)amino-, (Ci-C4alkyl)(Ci-C4alkyl)amino-, (Ci-C4alkyl), hydroxy(Ci-C4alkyl)-, amino(Ci-C4alkyl)-, (Ci-C4alkyl)amino(Ci-C4alkyl)-, (Ci-C4alkyl)(Ci-C4alkyl)amino(Ci-C4alkyl)-, Ci-C4alkoxy-, hydroxy(C2-C4alkoxy)-, amino(C2-C4alkoxy)-, (Ci-C4alkyl)amino(C2-C4alkoxy)-,
• R A1 and R A2 are each independently H, hydroxy, -0-P(0)(OH)2, -0-P(0)(R I R II )2, amino, (Ci-C4alkyl)amino-, (Ci-C4alkyl)(Ci-C4alkyl)amino-, (Ci-C4alkyl), hydroxy(Ci-C4alkyl)-, amino(Ci-C4alkyl)-, (Ci-C4alkyl)amino(Ci-C4alkyl)-, (Ci-C4alkyl)(Ci-C4alkyl)amino(Ci-C4alkyl)-, Ci-C4alkoxy-, hydroxy(C 2 -C4alkoxy)-, -(C 2 -C4alkoxy)-0-P(0)(OH) 2 , - ⁇ alkoxyj-O-PCOXR 1
• q is 0 and R A1 and R A2 are each independently H,
• q is 0 and R A1 and R A2 each independently H, (Ci-C6alkyl)oxy-, hydroxy(C2-C6alkyl)oxy-, -(C2-C4alkoxy)-0- P(0)(OH)2, -(C2-C4alkoxy)-0-P(0)(R I R II )2.
• q is 0 and R A1 and R A2 are each H.
• q is 0 and R A1 and R A2 are independently selected from H, -OCH2CH2CH2OH and -OCH3.
• R A2 and R A1 are each independently H, optionally substituted (Ci-C6alkyl), or optionally substituted (Ci-C6alkyl)oxy-, wherein Ci-C6alkyl of said optionally substituted (Ci-C6alkyl), or optionally substituted (Ci-C6alkyl)oxy- is optionally substituted with 1-4 substituents each independently selected from the group consisting of hydroxyl, -0-P(0)(OH) 2 , Ci-C4alkoxyl, -N(R e )(R , -COOH, optionally substituted phenyl, and optionally substituted 5-6 membered heterocycloalkyi, and each R e is independently selected from H, Ci-C4alkyl, -CO(Ci-C4alkyl), -OCO(Ci-C4alkyl), - (Ci-C4alkyl)NH 2 , -(Ci-C4al
• R A2 and R A1 are each independently H, optionally substituted (Ci-C6alkyl), or optionally substituted (Ci-C6alkyl)oxy-, and the Ci-C6alkyl of said optionally substituted (Ci-C6alkyl), optionally substituted (Ci-C6alkyl)oxy- is optionally substituted with 1-4 substituents each independently selected from the group consisting of hydroxyl, -0-P(0)(OH) 2 , -N(R e )(R , Ci-C4alkoxyl, phenyl, and optionally substituted 5-6 membered heterocycloalkyi containing at least one nitrogen or oxygen as a member of the ring, and each R e is each independently selected from H, Ci-C4alkyl, - (Ci-C4alkyl)NH2, or -(Ci-C4alkyl)Ci-C4alkoxy.
• q is 0 and at least one of R A2 or R A1 are each independently H, optionally substituted (Ci-C6alkyl), or optionally substituted (Ci-C6alkyl)oxy-, and the Ci-C6alkyl of said optionally substituted (Ci-C6alkyl), optionally substituted (Ci-C6alkyl)oxy- is optionally substituted with 1-4 substituents each independently selected from -N(R e )(R , tetrahydropyran, pyrrolidinyl, piperazinyl, piperidyl and morpholinyl and each R e is each independently selected from H, Ci-C4alkyl, -(Ci-C4alkyl)NH2, or -(Ci-C4alkyl)Ci-C4alkoxy.
• q is 0 and at least one of R A2 or R A1 are each independently H, optionally substituted (Ci-C6alkyl), or optionally substituted (Ci-C6alkyl)oxy-, and the Ci-C6alkyl of said optionally substituted (Ci-C6alkyl), optionally substituted (Ci-C6alkyl)oxy- is optionally substituted with 1-4 substituents each independently selected from
• each R e is each independently selected from H or Ci-C4alkyl.
• r is 0 and R B1 and R B2 are each independently H, optionally substituted Ci-C6alkyl, halo(Ci-C6alkyl), optionally substituted C2-C6alkenyl, optionally substituted C2-C6alkynyl, optionally substituted
• C3-C6cycloalkyl optionally substituted 4-6 membered heterocycloalkyi, optionally substituted phenyl, optionally substituted 5-6 membered heteroaryl, or optionally substituted 9-10 membered heteroaryl,
• Ci-Cealkyl optionally substituted C2-C6alkenyl, optionally substituted C2-C6alkynyl, optionally substituted C3-C6cycloalkyl, optionally substituted 4-6 membered heterocycloalkyl, optionally substituted phenyl, optionally substituted 5-6 membered heteroaryl, or optionally substituted 9-10 membered heteroaryl is optionally substituted by 1-4 substituents each independently selected from halogen, nitro, -R c , -OH, -OR c , -IMH2, -NR C R C ,
• r is 0 and R B1 and R B2 are each H.
• R B1 and R B2 are each independently H, optionally substituted Ci-C6alkyl, halo(Ci-C6alkyl), optionally substituted C2-C6alkenyl, optionally substituted C2-C6alkynyl, optionally substituted C3-C6cycloalkyl, optionally substituted 4-6 membered heterocycloalkyl, optionally substituted 5-6 membered heteroaryl or optionally substituted 9 membered heteroaryl.
• s is 0 and R C1 is H, halogen, or Ci-C4alkyl and R C2 is optionally substituted Ci-C4alkyl, wherein said optionally substituted Ci-C4alkyl group is optionally substituted by a substituent selected
• R C1 and R C2 are each independently H or Ci-C4alkyl.
• R C1 is Ci-C3alkyl, specifically methyl.
• R C2 is Ci-C3alkyl, specifically methyl or ethyl.
• R C2 is ethyl.
• R A1 and R A2 are each independently -CH2-, -NR e -, or -0-, and A, taken together with R A1 and R A2 , forms a linking group, wherein A is -halo(Ci-Ci2alkyl)-, optionally substituted -Ci-Cnalkyl-, optionally substituted -C2-Ci2alkenyl-, optionally substituted -C2-Ci2alkynyl-, optionally substituted -Ci-C6alkyl-0-Ci-C6alkyl-, optionally substituted -Ci-C6alkyl-NR a -Ci-C6alkyl-, optionally substituted -C 1 -Cea I ky I - (C3 -C6cyc loa I kyl ) -C 1 -C6a I ky I - , optionally substituted
• heterocycloalkyl -Ci-C6alkyl-, or optionally substituted -Ci-C6alkyl-(5-6 membered heteroaryl)-Ci-C6alkyl-, wherein the alkyl moiety of said optionally substituted -Ci-Ci2alkyl-, optionally substituted -C2-Ci2alkenyl-, optionally substituted -C2-Ci2alkynyl-, optionally substituted -Ci-C6alkyl-0-Ci-C6alkyl-, optionally substituted
• -Ci-C6alkyl-phenyl-Ci-C6alkyl-, optionally substituted -Ci-C6alkyl-(4-6 membered heterocycloalkyl)-Ci-C6alkyl-, or optionally substituted -Ci-C6alkyl-(5-6 membered heteroaryl)-Ci-C6alkyl- is optionally substituted by 1-4 substituents each independently selected from halogen, halo(Ci-C4alkyl), -OH, - OR c , -IMH2, -NR c R d , -OCOR -CO2H, -C0 2 R c , -SOR c , -S0 2 R c , -CONH2, -CONR c R d , -SO2 NH2, -S0 2 NR c R d , -OCONH2, -OCONR c R d , -NR
• -Ci-C6alkyl-phenyl-Ci-C6alkyl-, optionally substituted -Ci-C6alkyl-(4-6 membered heterocycloalkyl)-Ci-C6alkyl-, or optionally substituted -Ci-C6alkyl-(5-6 membered heteroaryl)-Ci-C6alkyl- is optionally substituted by 1-4 substituents each independently selected from halogen, hydroxy, amino, (Ci-C4alkyl)amino-, (Ci-C4alkyl)(Ci-C4alkyl)amino-, Ci-C4alkyl, halo(Ci-C4alkyl), halo(Ci-C4alkoxy)-, Ci-C4alkoxy-, hydroxy-(C2-C4alkoxy)-, and Ci-C4alkoxy-(Ci-C4alkoxy)-.
• R A1 and R A2 are each independently -CH2-, -NR e -, or -0-, and A, taken together with R A1 and R A2 , forms a inking group, wherein A is -halo(Ci-Ci2alkyl)-, optionally substituted -Ci-Cnalkyl-, optionally substituted -C2-Ci2alkenyl-, optionally substituted -C2-Ci2alkynyl-, optionally substituted -Ci-C6alkyl-0-Ci-C6alkyl-, optionally substituted -Ci-C6alkyl-NR a -Ci-C6alkyl-, optionally substituted -C 1 -Cea I ky I - (C3 -C6cyc loa I kyl ) -C 1 -C6a I ky I - , optionally substituted
• heterocycloalkyl -Ci-C6alkyl-, or optionally substituted -Ci-C6alkyl-(5-6 membered heteroaryl)-Ci-C6alkyl-,
• -Ci-C6alkyl-phenyl-Ci-C6alkyl-, optionally substituted -Ci-C6alkyl-(4-6 membered heterocycloalkyl)-Ci-C6alkyl-, or optionally substituted -Ci-C6alkyl-(5-6 membered heteroaryl)-Ci-C6alkyl- is optionally substituted by 1-4 substituents each independently selected from halogen, halo(Ci-C4alkyl), -OH, -0-P(0)(OH)2, -0-P(0)(RiRii)2, -OR c , -NH 2 , -NR c R d , -OCOR c , -CO2H, -C0 2 R c , -SOR c , -S0 2 R c , -CONH2, -CONR c R d , -SO2NH2, -S0 2 NR c R
• q is 1 and A, taken together with R A1 and R A2 , forms a 4-8 membered linking group. In a further embodiment, q is 1 and A, taken together with R A1 and R A2 , forms a 4-6 membered linking group. In a still further embodiment, q is 1 and A, taken together with R A1 and R A2 , forms a 5 membered linking group.
• R A1 and R A2 are each independently -CH2-, -NR e -, or -0-, and A is a substituted -C2-Cioalkyl- group or is an unsubstituted -C2-Cioalkyl-, -C2-Cioalkenyl-, -C2-Cioalkynyl-, -Ci-C4alkyl-0-Ci-C4alkyl-, or
• -Ci-C4alkyl-NR a -Ci-C4alkyl- group said substituted -C2-Cioalkyl- group is substituted by 1-4 substituents each independently selected from halogen, hydroxy, amino, (Ci-C4alkyl)amino-, (Ci-C4alkyl)(Ci-C4alkyl)amino-, halo(Ci-C4alkyl), halo(Ci-C4alkoxy)-, and Ci-C4alkoxy-.
• R A1 and R A2 are each independently -CH2-, -NR e -, or -0-, and A is a substituted -C2-Cioalkyl- group or is an unsubstituted -C2-Cioalkyl-, -C2-Cioalkenyl-, -C2-Cioalkynyl-, -Ci-C4alkyl-0-Ci-C4alkyl-, or -Ci-C4alkyl-NR a -Ci-C4alkyl- group, said substituted -C2-Cioalkyl- group is substituted by 1-4 substituents each independently selected from halogen, hydroxy, -0-P(0)(OH)2, -0- P(0)(R I R II )2, amino, (Ci-C4alkyl)amino-, (Ci-C4alkyl)(Ci-C4alkyl)amino-, halo
• R A1 and R A2 are each independently -CH2-, -NR e -, or -0-, and A is a substituted -C2-Csalkyl- group or is an unsubstituted -C2-Csalkyl-,
• R A1 and R A2 are each independently -CH2-, -NR e -, or -0-, and A is a substituted -C2-Csalkyl- group or is an unsubstituted -C2-Csalkyl-,
• said substituted -C2-Csalkyl- group is substituted by 1-2 substituents each independently selected from halogen, hydroxy, -0-P(0)(0H)2, amino, (Ci-C4alkyl)amino-, (Ci-C4alkyl)(Ci-C4alkyl)amino-, halo(Ci-C4alkyl), halo(Ci-C4alkoxy)-, and Ci-C4alkoxy-.
• R A1 and R A2 are each independently -CH2-, -NR e -, or -0-, and A is a substituted -C2-C6alkyl- group or is an unsubstituted -C2-C6alkyl-,
• said substituted -C2-C6alkyl- group is substituted by 1-2 substituents each independently selected from halogen, hydroxy, amino, (G-C4alkyl)amino-, (Ci-C4alkyl)(Ci-C4alkyl)amino-, halo(Ci-C4alkyl), halo(Ci-C4alkoxy)-, and Ci-C4alkoxy-.
• R A1 and R A2 are each independently -CH2-, -NR e -, or -0-, and A is a substituted -C2-C6alkyl- group or is an unsubstituted -C2-C6alkyl-,
• said substituted -C2-C6alkyl- group is substituted by 1-2 substituents each independently selected from halogen, hydroxy,-0-P(0)(OH) 2 , amino, (G-C4alkyl)amino-, (Ci-C4alkyl)(Ci-C4alkyl)amino-, halo(Ci-C4alkyl), halo(Ci-C4alkoxy)-, and Ci-C4alkoxy-.
• R A1 and R A2 are each independently -CH2- or -0-, and A is a -C2-C4alkyl-, -C2-C4alkenyl-, or -C2-C4alkynyl- group.
• q is 1, R A1 and R A2 are each -0-, and A is -CH2CH2CH2-, wherein A, taken together with R A1 and R A2 , form a -OCH2CH2CH2O- group.
• q is 1, R A1 and R A2 are each -0-, and A is -Ch -phenyl-CI- -, wherein A, taken together with R A1 and R A2 , form a -OCH2-phenyl-CH20- group.
• q is 1, A, taken together with R A1 and R A2 , form a -OCh -phenyl-CI- O- group, wherein the -OCH2- groups are located 1, 4 on the phenyl ring moiety.
• the length of the linking groups defined herein represents the lowest number of atoms in a direct chain composed of -R A1 -A-R A2 -and/or-R B1 -B-R B2 -and/or -R C1 -C-R C2 -.
• the linking group -R B1 -B-R B2 - may be represented as -(CH2)-phenyl-(CH2)-.
• This linking group is characterized as a 4-membered linking group when the 2 -(CH2)- moieties are located on adjacent carbon atoms of the phenyl ring (1,2 substituted phenyl).
• this linking group is characterized as a 6-membered linking group when the 2 -(CH2)- moieties are substituted at para positions on the phenyl ring (1,4 substituted phenyl).
• any alkyl, alkenyl, or alkynyl group or moiety of A, B or C is a straight or branched-alkyl, alkenyl, or alkynyl group or moiety.
• -Ci-Cioalkyl- may contain an 8-membered linking group having a (Ci-C4alkyl) branching group or 2-4 (Ci-C3alkyl) branching groups, for example, 4 branching methyl groups (2 gem-dimethyl groups) or 2 branching methyl groups.
• r is 1 and R B1 and R B2 are each independently -CH2-, and B, taken together with R B1 and R B2 , forms a linking group, wherein B is a bond or B is -halo(Ci-Cioalkyl)-, optionally substituted -Ci-Cioalkyl-, optionally substituted -C2-Goalkenyl-, optionally substituted -C2-Cioalkynyl-, optionally substituted -Ci-C6alkyl-0-Ci-C6alkyl-, optionally substituted -Ci-C6alkyl-NR a -Ci-C6alkyl-, optionally substituted C3-C6cycloalkyl, optionally substituted phenyl, optionally substituted 4-6 membered heterocycloalkyl, optionally substituted 5-6 membered heteroaryl, optionally substituted -C 1 -C 4 a I ky I
• -Ci-C 4 alkyl-phenyl-Ci-C 4 alkyl-, optionally substituted -Ci-C 4 alkyl-(4-6 membered heterocycloalkyl)-Ci-C4alkyl-, or optionally substituted -Ci-C 4 alkyl-(5-6 membered heteroaryl-Ci-C4alkyl)- is optionally substituted by 1 or 2 substituents each independently selected from halogen, halo(Ci-C4alkyl), -OH, -OR c , -NH 2 , -NR c R d , -OCOR c , -CO2H, -C0 2 R c , -SOR c , -SO2R - CONH2, -CONR c R d , -SO2NH2, -S0 2 NR c R d , -OCONH2, -OCONR c R d , -NR
• -Ci-C4alkyl-phenyl-Ci-C4alkyl-, optionally substituted -Ci-C4alkyl-(4-6 membered heterocycloalkyl)-Ci-C4alkyl-, or optionally substituted -Ci-C4alkyl-(5-6 membered heteroaryl)-Ci-C4alkyl- is optionally substituted by 1-4 substituents each independently selected from halogen, hydroxy, amino, (Ci-C4alkyl)amino-, (Ci-C4alkyl)(Ci-C4alkyl)amino-, Ci-C4alkyl, halo(Ci-C4alkyl), halo(Ci-C4alkoxy)-, Ci-C4alkoxy-, hydroxy-(C2-C4alkoxy)-, and Ci-C4alkoxy-(Ci-C4alkoxy)-.
• r is 1 and R B1 and R B2 are each independently -CH2-, and B, taken together with R B1 and R B2 , forms a linking group, wherein B is a bond or B is -halo(Ci-Cioalkyl)-, optionally substituted -Ci-Cioalkyl-, optionally substituted -C2-Goalkenyl-, optionally substituted -C2-Cioalkynyl-, optionally substituted -Ci-C6alkyl-0-Ci-C6alkyl-, optionally substituted -Ci-C6alkyl-NR a -Ci-C6alkyl-, optionally substituted C3-C6cycloalkyl, optionally substituted phenyl, optionally substituted 4-6 membered heterocycloalkyi, optionally substituted 5-6 membered heteroaryl, optionally substituted -C 1 -C 4 a I ky I
• heterocycloalkyl -Ci-C4alkyl-, or optionally substituted -Ci-C alkyl-(5-6 membered heteroaryl)-Ci-C4alkyl-,
• -Ci-C 4 alkyl-phenyl-Ci-C 4 alkyl-, optionally substituted -Ci-C 4 alkyl-(4-6 membered heterocycloalkyl)-Ci-C4alkyl-, or optionally substituted -Ci-C 4 alkyl-(5-6 membered heteroaryl-Ci-C4alkyl)- is optionally substituted by 1 or 2 substituents each independently selected from halogen, halo(Ci-C4alkyl), -OH, -0-P(0)(OH)2, -0- P(0)(R I R II )2,-OR c , -NH2, -NR c R d , -OCOR c , -CO2H, -C0 2 R c , -SOR c , -S0 2 R c , -CONH2, -CONR c R d , -SO2NH2, -S0 2 NR c R d
• Ci-C4alkyl halo(Ci-C4alkyl), halo(Ci-C4alkoxy)-, Ci-C4alkoxy-,
• r is 1, R B1 and R B2 are each independently -CH2-, and B, taken together with R B1 and R B2 , forms a 2-6 membered linking group.
• r is 1, R B1 and R B2 are each independently -CH2-, and B, taken together with R B1 and R B2 , forms a 3-6 membered linking group.
• r is 1, R B1 and R B2 are each independently -CH2-, and B, taken together with R B1 and R B2 , forms a 4-5 membered linking group.
• B is a bond
• r is 1, R B1 and R B2 are each independently -CH2-, and B is a substituted -G-Goalkyl- group or is an unsubstituted -Ci-Cioalkyl-, -C2-Cioalkenyl-,
• substituted -G-Goalkyl- group is substituted by 1-4 substituents each independently selected from halogen, hydroxy, amino, (G- alkyl)amino-, (G- alkylXG- alkyOamino-, halo(G-Goalkyl), halo(G-C4alkoxy)-, G- alkoxy-, hydroxy-(C2-C4alkoxy)-,
• R B1 and R B2 are each independently -CH2-, and B is a substituted -Ci-CioalkyI- group or is an unsubstituted -Ci-CioalkyI-, -C2-Cioalkenyl-, -C2-Cioalkynyl-, -Ci-C6alkyl-0-Ci-C6alkyl-, or -Ci-C6alkyl-NR a -Ci-C6alkyl- group
• said substituted -G-Goalkyl- group is substituted by 1-4 substituents each independently selected from halogen, hydroxy, -0-P(0)(OH) 2 , -0-P(0)(R I R II )2, amino, (G-Galkyl)amino-, (Ci-C6alkyl)(Ci-C6alkyl)amino-, halo(Ci-C6alkyl), halo
• R B1 and R B2 are each independently -CH2-, and B is a substituted -Ci-CioalkyI- group or is an unsubstituted -Ci-CioalkyI-, -C2-Cioalkenyl-, -C2-Cioalkynyl-, -Ci-C6alkyl-0-Ci-C6alkyl-, or -Ci-C6alkyl-NR a -Ci-C6alkyl- group, said substituted -Ci-CioalkyI- group is substituted by 1-4 substituents each independently selected from halogen, hydroxy, amino, (G-C4alkyl)amino-, (Ci-C4alkyl)(Ci-C4alkyl)amino-, halo(Ci-C4alkyl), halo(Ci-C4alkoxy)-, and Ci-C4alkoxy
• r is 1, R B1 and R B2 are each independently -CH2-, and B is a substituted -G-Goalkyl- group or is an unsubstituted -G-Goalkyl-, -G-Goalkenyl-,
• -G-Goalkynyl-, -G-C6alkyl -G-C6alkyl-, or -G-C6alkyl-NR a -G-C6alkyl- group said substituted -G-Goalkyl- group is substituted by 1-4 substituents each independently selected from halogen, hydroxy, -0-P(0)(OH) 2 , amino, (G-GalkyOamino-, (G-Galkyl)(G-Galkyl)amino-, halo(G-Galkyl), halo(G-C4alkoxy)-, and G-C4alkoxy-.
• r is 1, R B1 and R B2 are each independently -CH2-, and B is a substituted -G- alkyl- group or is an unsubstituted -G- alkyl-, -Q- alkenyl-,
• -G-C8alkynyl- -G- alkyl-O-G- alkyl-, or -G-C4alkyl-NR a -G-C4alkyl- group
• said substituted -G- alkyl- group is substituted by 1-4 substituents each independently selected from halogen, hydroxy, amino, (G-Galkyl)amino-, (G-Galkyl)(G-Galkyl)amino-, halo(G-Galkyl), halo(G-C4alkoxy)-, and G-Galkoxy-.
• r is 1, R B1 and R B2 are each independently -CH2-, and B is a substituted -G-Csalkyl- group or is an unsubstituted -G-Csalkyl-, -Q-Csalkenyl-,
• substituted -G- alkyl- group is substituted by 1-4 substituents each independently selected from halogen, hydroxy, -0-P(0)(OH) 2 , -0-P(0)(R I R II )2, amino, (G-C4alkyl)amino-,
• r is 1, R B1 and R B2 are each independently -CH2-, and B is a substituted -G-C6alkyl- group or is an unsubstituted -Ci-C6alkyl-, -C2-C6alkenyl-,
• -C2-C6alkynyl- -Ci-C2alkyl-0-Ci-C2alkyl-, or -Ci-C2alkyl-NR a -Ci-C2alkyl- group
• said substituted -Ci-C6alkyl- group is substituted by 1-2 substituents each independently selected from halogen, hydroxy, amino, (Ci-C4alkyl)amino-, (Ci-C4alkyl)(Ci-C4alkyl)amino-, halo(Ci-C4alkyl), halo(Ci-C4alkoxy)-, and Ci-C4alkoxy-.
• r is 1, R B1 and R B2 are each independently -CH2-, and B is a substituted -G-C6alkyl- group or is an unsubstituted -Ci-C6alkyl-, -C2-C6alkenyl-,
• r is 1, R B1 and R B2 are each independently -CH2-, and B is a substituted -Q-Galkyl- group or is an unsubstituted -Q-Galkyl-, -C2-C4alkenyl-,
• -Q-Galkyl- group is substituted by 1-2 substituents each independently selected from halogen, hydroxy, amino, (G-Gialkyl)amino-, (Ci-C4alkyl)(G-C4alkyl)amino-, halo(G-Gialkyl), halo(G-C4alkoxy)-, and G-C4alkoxy-.
• r is 1, R B1 and R B2 are each independently -CH2-, and B is a substituted -Q- alkyl- group or is an unsubstituted -Q- alkyl-, -C2-C4alkenyl-,
• -Q-Galkyl- group is substituted by 1-2 substituents each independently selected from halogen, hydroxy, -0-P(0)(OH) 2 , amino, (G-GalkyOamino-,
• G-C4alkyl (G-C4alkyl)amino-, halo(G-C4alkyl), halo(G-C4alkoxy)-, and G-C4alkoxy-.
• r is 1, B, taken together with R B1 and R B2 , form a -CH2CI- CHCH2-.
• s is 1 and R C1 and R C2 are each independently -CH2-, and C, taken together with R C1 and R C2 , forms a linking group, wherein C is -halo(Ci-Ci2alkyl)-, optionally substituted -Ci-Ci2alkyl-, optionally substituted -C2-Ci2alkenyl-, optionally substituted -C2-Ci2alkynyl-, optionally substituted
• -Ci-C6alkyl-phenyl-Ci-C6alkyl-, optionally substituted -Ci-C6alkyl-(4-6 membered heterocycloalkyl)-Ci-C6alkyl-, or optionally substituted -Ci-C6alkyl-(5-6 membered heteroaryl)-Ci-C6alkyl- is optionally substituted by 1-4 substituents each independently selected from halogen, hydroxy, amino, (Ci-C4alkyl)amino-, (Ci-C4alkyl)(Ci-C4alkyl)amino-, Ci-C4alkyl, halo(Ci-C4alkyl), halo(Ci-C4alkoxy)-, Ci-C4alkoxy-, hydroxy-(C2-C4alkoxy)-, and Ci-C4alkoxy-(Ci-C4alkoxy)-.
• s is 1 and R C1 and R C2 are each independently -CH2-, and C, taken together with R C1 and R C2 , forms a linking group, wherein C is -halo(Ci-Ci2alkyl)-, optionally substituted -Ci-Ci2alkyl-, optionally substituted -C2-Ci2alkenyl-, optionally substituted -C2-Ci2alkynyl-, optionally substituted
• heterocycloalkyl -Ci-C6alkyl-, or optionally substituted -Ci-C6alkyl-(5-6 membered heteroaryl)-Ci-C6alkyl-,
• s is 1, R C1 and R C2 are each independently -CH2-, and C, taken together with R C1 and R C2 , forms a 4-8 membered linking group. In a further embodiment, s is 1 and C, taken together with R C1 and R C2 , forms a 4-6 membered linking group. In a still further embodiment, s is 1 and C, taken together with R C1 and R C2 , forms a 5 membered linking group.
• R C1 and R C2 are each independently -CH2-, and C is a substituted -C2-Goalkyl- group or is an unsubstituted -C2-Cioalkyl-, -C2-Cioalkenyl-,
• substituted -C2-Goalkyl- group is substituted by 1-4 substituents each independently selected from halogen, hydroxy, amino, (G-C4alkyl)amino-, (Ci-C4alkyl)(Ci-C4alkyl)amino-, halo(Ci-C4alkyl), halo(Ci-C4alkoxy)-, and Ci-C4alkoxy-.
• R C1 and R C2 are each independently -CH2-, and C is a substituted -C2-Cioalkyl- group or is an unsubstituted -C2-Cioalkyl-, -C2-Cioalkenyl-,
• substituted -C2-Goalkyl- group is substituted by 1-4 substituents each independently selected from halogen, hydroxy, -0-P(0)(OH)2, amino, (G-C4alkyl)amino-,
• s is 1, R C1 and R C2 are each independently -CH2-, and C is a substituted -C2-Csalkyl- group or is an unsubstituted -C2-Csalkyl-, -C2-Csalkenyl-,
• substituted -C2-Csalkyl- group is substituted by 1-2 substituents each independently selected from halogen, hydroxy, amino, (G-Gialkyl)amino-, (Ci-Galkyl)(Ci-Gialkyl)amino-, halo(G-Gialkyl), halo(G-Gialkoxy)-, and G-C4alkoxy-.
• s is 1, R C1 and R C2 are each independently -CH2-, and C is a substituted -C2-Csalkyl- group or is an unsubstituted -C2-Csalkyl-, -C2-Csalkenyl-,
• R C1 and R C2 are each independently -CH2-, and C is a substituted -C2-C6alkyl- group or is an unsubstituted -C2-C6alkyl-, -C2-C6alkenyl-,
• R C1 and R C2 are each independently -CH2-, and C is a substituted -C2-C6alkyl- group or is an unsubstituted -C2-C6alkyl-, -C2-C6alkenyl-,
• R C1 and R C2 are each independently -CH2-, and C is a -C2-C4alkyl-, -C2-C4alkenyl-, or -C2-C4alkynyl- group.
• s is 1, R C1 and R C2 are each independently -CH2-, and C is -CH2CH2CH2-, wherein C, taken together with R C1 and R C2 , form
• R 4 and R 6 are each independently selected from H, halogen, halofCi-Cealkyl), halo(Ci-C6alkoxy)-,
• R 4 and R 6 are each H.
• R 14 is optionally substituted Ci-C4alkyl, wherein said optionally substituted Ci-C4alkyl is optionally substituted by a substituent selected from -OR c , -NR c R d , -C02R C , -CONR c R d , -S02NR c R d , and -OCONR c R d .
• R 16 is H, halogen, or Ci-C4alkyl.
• R 15 and R 17 are each independently H, cyclopropyl, or Ci-C4alkyl.
• R 14 , R 15 , R 16 , and R 17 are each independently H or Ci-C4alkyl.
• R 16 is H.
• R 14 , R 15 , and R 17 are each independently Ci-C4alkyl.
• R 14 , R 15 , and R 17 are each independently Ci-C3alkyl, specifically, methyl or ethyl. In a selected embodiment, R 14 is ethyl.
• R 15 and R 17 are each methyl.
• R a is H, - R c , -COR c , -CO2H, -C0 2 R c , -SOR c , -S0 2 R c , -CONH2, -CONR c R d , -SO2NH2, or -S0 2 NR c R d .
• R a is H, Ci-C4alkyl, -CO(Ci-C4alkyl), -CO(Ci-C4alkyl)-OH, -CO(Ci-C4alkyl)-0-(Ci-C4alkyl), -CO(Ci-C4alkyl)-NH 2 , -CO(Ci-C4alkyl)-NH(Ci-C4alkyl), or -CO(Ci-C4alkyl)-N(Ci-C4alkyl)(Ci-C4alkyl).
• One embodiment of this invention is directed to a compound Formula (I-N), Formula (I) or Formula (I-P) wherein:
• R A1 and R A2 are independently selected from H, -OCH2CH2CH2OH and - OCH 3 ; or
• R A1 and R A2 are each -0-, and A is -CH2CH2CH2-;
• r is 0 and R B1 and R B2 are each H; or
• R B1 and R B2 are each independently -CH2-, and B
• R C1 is methyl and R C2 is ethyl; or
• R C1 and R C2 are each independently -CH2-, and C is -CH2CH2CH2-;
• R 3 and R 5 are each -CONH2;
• R 4 and R 6 are each H
• R 14 is ethyl
• R 15 is methyl
• R 16 is H
• R 17 is methyl
• the compound of invention has Formula (I-N-B 1 )
• R 3 and R 5 are each independently -CON(R d )(R , or one of R 3 and R 5 is -CON(R d )(R , and the other of R 3 and R 5 is H, COOH or -C02(R C );
• R c is Ci-C4alkyl
• R B1 and R B2 are each independently -CH2-;
• R A2 and R A1 are each independently H, halogen, hydroxyl, -0-P(0)(OH) 2 ,
• Ci-C6alkyl of said optionally substituted (Ci-C6alkyl), or optionally substituted (G-C6alkyl)oxy- is optionally substituted with 1-4 substituents each independently selected from the group consisting of hydroxyl, -0-P(0)(OH)2, - Ci-C4alkoxyl, -N(R e )(R , -CO2(R , optionally substituted phenyl, and optionally substituted 5-6 membered heterocycloalkyl; wherein said optionally substituted phenyl, or 5-6 membered heterocycloalkyl is optionally substituted by 1-4 substituents each independently selected from halogen, hydroxy, -0-P(0)(OH) 2 , amino, (G-CealkyOamino-,
• each R d is independently H or Ci-C4alkyl
• R e is selected from H, (Ci-C4alkyl), -CO(Ci-C4alkyl), -OCO(Ci-C4alkyl), -(Ci-C4alkyl)-
• each occurrence of R f is H or (Ci-C4alkyl);
• R 4 and R 6 are H
• R 14 is Ci-C4alkyl
• R C1 is H or Ci-C4alkyl
• R C2 is Ci-C4alkyl
• R 15 is H or Ci-C4alkyl
• R 16 is H or Ci-C4alkyl
• R 17 is H or Ci-C4alkyl
• each occurrence of R 1 and R n are independently (Ci-C6alkyl)oxy-,
• the compound of invention has Formula ( ⁇ - ⁇ - ⁇ ')
• R 3 and R 5 are each independently -CON(R d )(R , or one of R 3 and R 5 is -CON(R d )(R , and the other of R 3 and R 5 is H, COOH or -C02(R C ); R c is Ci-Cialkyl;
• R B1 and R B2 are each independently -CH2-;
• R A2 and R A1 are each independently H, halogen, hydroxyl, -0-P(0)(OH) 2 , -0- P(0)(R I R II )2, optionally substituted (Ci-Cealkyl), or optionally substituted (Ci- C6alkyl)oxy-,
• Ci-C6alkyl of said optionally substituted (Ci-C6alkyl), or optionally substituted (G-C6alkyl)oxy- is optionally substituted with 1-4 substituents each independently selected from the group consisting of hydroxyl, -0-P(0)(0H)2, G-Oalkoxyl, -N(R e )(R , -C0 2 (R , optionally substituted phenyl, and optionally substituted 5-6 membered heterocycloalkyl; wherein said optionally substituted phenyl, or 5-6 membered heterocycloalkyl is optionally substituted by 1-4 substituents each independently selected from halogen, hydroxy, -0-P(0)(OH) 2 , -0-P(0)(R I R II )2, amino, (G-CealkyOamino-, (Ci-C6alkyl)(Ci-C6alkyl)amino-, halo(Ci-C6alkyl),
• R e is selected from H, (Ci-C4alkyl), -C0(Ci-C4alkyl), -0C0(G-C4alkyl), -(G-Galkyl)-
• each occurrence of R f is H or (Ci-C4alkyl);
• R 4 and R 6 are H
• R 14 is G-Oalkyl
• R C1 is H or Ci-C4alkyl
• R C2 is G-Oalkyl
• R 15 is H or G-Oalkyl
• R 16 is H or Ci-C4alkyl
• R 17 is H or Ci-C4alkyl
• each occurrence of R 1 and R n are independently (Ci-C6alkyl)oxy-,
• the compound of invention is Formula ( ⁇ - ⁇ '
• R 3 and R 5 are each independently -CON(R d )(R , or one of R 3 and R 5 is -CON(R d )(R , and the other of R 3 and R 5 is H or -C02(R C );
• R c is Ci-C4alkyl
• R B1 and R B2 are each independently -CH2-;
• B is -halo(Ci-C5alkyl), unsubstituted -Ci-Csallkyl, or unsubstituted -C2-C5alkenyl-;
• R A2 and R A1 are each independently H, halogen, hydroxyl, optionally substituted (Ci-
• Ci-C6alkyl of said optionally substituted (Ci-C6alkyl), or optionally substituted (Ci-C6alkyl)oxy- is optionally substituted with 1-4 substituents each independently selected from the group consisting of hydroxyl, Ci-C4alkoxyl, - N(R e )(R , -CO2(R , optionally substituted phenyl, and optionally substituted 5- 6 membered heterocycloalkyl; wherein said optionally substituted phenyl, or 5-6 membered heterocycloalkyl is optionally substituted by 1-4 substituents each independently selected from halogen, hydroxy, -0-P(0)(OH)2, -0- P(0)(R I R II )2, amino, (G-C6alkyl)amino-, (Ci-C6alkyl)(Ci-C6alkyl)amino-, halo(Ci-C6alkyl), hydroxy-(Ci-C4alkyl
• each R d is independently H or Ci-C4alkyl
• R e is selected from H, (Ci-C4alkyl), -CO(Ci-C4alkyl), -OCO(Ci-C4alkyl),
• each R f is H or (G-C4alkyl);
• R 4 and R 6 are H
• R 14 is Ci-dalkyl
• R C1 is H or Ci-Oalkyl
• R C2 is Ci-dalkyl
• R 15 is H or G-Oalkyl
• R 16 is H or Ci-dalkyl
• R 17 is H or G-C4alkyl
• each occurrence of R 1 and R n are independently (Ci-C6alkyl)oxy-,
• the compound of invention is Formula (I-N-bO,
• R A2 and R A1 are each independently H, halogen, hydroxyl, -0-P(0)(OH) 2 ,
• Ci-C6alkyl of said optionally substituted (Ci-Cealkyl) or optionally substituted (Ci-C6alkyl)oxy- is optionally substituted with 1-4 substituents each independently selected from the group consisting of hydroxyl, Ci-C4alkoxyl, -N(R e )(R f ), -C02(R f ), optionally substituted phenyl, and optionally substituted 5- 6 membered heterocycloalkyl, and wherein said optionally substituted phenyl, or 5-6 membered heterocycloalkyl is optionally substituted by 1-4 substituents each independently selected from halogen, hydroxy, -0-P(0)(OH)2, -0- P(0)(R I R II )2, amino, (G-C6alkyl)amino-, (Ci-C6alkyl)(Ci-C6alkyl)amino-, halo(Ci-C 6 alkyl), hydroxy-(Ci
• R e is selected from H, (Ci-C4alkyl), -C0(G-C4alkyl), -0C0(Ci-C4alkyl),
• each R f is H or (Ci-C4alkyl);
• R 14 is Ci-C4alkyl
• R C2 is Ci-C4alkyl
• R 15 is Ci-C4alkyl
• R 17 is Ci-C4alkyl
• each occurrence of R 1 and R n are independently (Ci-C6alkyl)oxy-,
• the compound of invention has Formula (I-P-bO,
• Formula (I-P-b') B is -halo(Ci-C5alkyl), unsubstituted -Ci-Csallkyl, or unsubstituted -C2-C5alkenyl-;
• R A2 and R A1 are each independently H, halogen, hydroxyl, -0-P(0)(OH) 2 ,
• Ci-C6alkyl of said optionally substituted (Ci-C6alkyl), or optionally substituted (G-C6alkyl)oxy- is optionally substituted with 1-4 substituents each independently selected from the group consisting of hydroxyl, Ci-C4alkoxyl, -N(R e )(R f ), -C02(R f ), optionally substituted phenyl, and optionally substituted 5 6 membered heterocycloalkyl, and wherein said optionally substituted phenyl, or 5-6 membered heterocycloalkyl is optionally substituted by 1-4 substituents each independently selected from halogen, hydroxy, -0-P(0)(OH)2,
• R e is selected from H, (Ci-C4alkyl), -CO(Ci-C4alkyl), -OCO(G-C4alkyl),
• each R f is H or (Ci-C4alkyl);
• R 14 is Ci-C4alkyl
• R C2 is Ci-C4alkyl
• R 15 is Ci-C4alkyl
• R 17 is Ci-C4alkyl
• each occurrence of R 1 and R n are independently (Ci-C6alkyl)oxy-,
• the compound of invention has Formula (l-b r ),
• B is -halo(Ci-C5alkyl), unsubstituted -Ci-Csallkyl, or unsubstituted -C2-C5alkenyl-;
• R A2 and R A1 are each independently H, halogen, optionally substituted (Ci-C6alkyl), or optionally substituted (Ci-C6alkyl)oxy-,
• Ci-C6alkyl of said optionally substituted (Ci-C6alkyl), or optionally substituted (G-C6alkyl)oxy- is optionally substituted with 1-4 substituents each independently selected from the group consisting of hydroxyl, Ci-C4alkoxyl, -N(R e )(R f ), -C02(R f ), optionally substituted phenyl, and optionally substituted 5- 6 membered heterocycloalkyl, and wherein said optionally substituted phenyl, or 5-6 membered heterocycloalkyl is optionally substituted by 1-4 substituents each independently selected from halogen, hydroxy, amino, (G-C6alkyl)amino-, (Ci-C6alkyl)(Ci-C6alkyl)amino-, halo(Ci-C6alkyl), hydroxy-(Ci-C4alkyl)-, halo(Ci-C4alkoxy)-
• R e is H, (Ci-C4alkyl), -CO(Ci-C4alkyl), -OCO(Ci-C4alkyl), or -C0 2 (Ci-C4alkyl), each occurrence of R f is H or (Ci-C4alkyl);
• R 14 is Ci-C4alkyl
• R C2 is Ci-C4alkyl
• R 15 is Ci-C4alkyl
• R 17 is Ci-C4alkyl
• each occurrence of R 1 and R n are independently (Ci-C6alkyl)oxy-, a tautomer, a salt, or a prodrug thereof.
• each R f is independently H or (Ci-C4alkyl).
• the compound of Formula ( ⁇ - ⁇ - ⁇ '), ( ⁇ - ⁇ - ⁇ '), (I-N-b 1 ), or (I-P-bO wherein at least one of R A2 or R A1 is independently H, halogen, optionally substituted (Ci- Cealkyl), or optionally substituted (Ci-C6alkyl)oxy-, and the Ci-C6alkyl of said optionally substituted (Ci-C6alkyl), optionally substituted (Ci-C6alkyl)oxy- is optionally substituted with 1-4 substituents each independently selected from -N(R e )(R , tetrahydropyran, pyrrolidinyl, piperazinyl, piperidyl and morpholinyl, each R e is independently selected from H, (Ci-C4alkyl), -(Ci-C4alkyl)-NH2, or -(Ci-C4alkyl) Ci-C4alkoxy and each R
• B is unsubstituted -Ci-Csallkyl, or unsubstituted -C2-C5alkenyl-;
• R A2 and R A1 are each independently H, halogen, optionally substituted (Ci-C6alkyl), or optionally substituted (Ci-C6alkyl)oxy-,
• Ci-C6alkyl of said optionally substituted (Ci-C6alkyl), or optionally substituted (Ci-C6alkyl)oxy- is optionally substituted with 1-2 substituents each independently selected from the group consisting of hydroxyl, Ci-C4alkoxyl,
• R e is H, (Ci-C4alkyl), -CO(Ci-C4alkyl), -OCO(Ci-Oalkyl), or -CQ_(Ci-Cialkyl), each occurrence of R f is H or (Ci-C4alkyl);
• R 14 is Ci-dalkyl
• R C2 is Ci-dalkyl
• R 15 is Ci-Cialkyl
• R 17 is Ci-dalkyl
• each occurrence of R 1 and R n are independently (Ci-C6alkyl)oxy-,
• B is unsubstituted -C2-C5alkenyl-
• R A2 and R A1 are each independently H, optionally substituted (Ci-CealkyI), or optionally substituted (G-C6alkyl)oxy-,
• Ci-C6alkyl of said optionally substituted (Ci-CealkyI), or optionally substituted (G-C6alkyl)oxy- is optionally substituted with 1 substituents each independently selected from the group consisting of hydroxyl, Ci-C4alkoxyl, unsubstituted 5-6 membered heterocycloalkyl,
• R 14 is G-Galkyl
• R C2 is Ci-dalkyl
• R 15 is Ci-C4alkyl
• R 17 is G-Galkyl
• B is unsubstituted ethenyl
• R A2 and R A1 are each independently H or optionally substituted (Ci-C6alkyl)oxy-, wherein Ci-C6alkyl of said optionally substituted (Ci-C6alkyl)oxy- is optionally substituted with one substituent selected from hydroxyl or unsubstituted morpholinyl;
• R 14 is methyl or ethyl
• R C2 is methyl or ethyl
• R 15 is methyl or ethyl
• R 17 is methyl or ethyl
• P is an integer among 1 to 6
• R A and R B are independently H
• R A and R B form an optionally substituted 5 or 6 membered heterocyclic ring, wherein the heterocyclic ring is selected from the group consisting of morpholinyl, piperidinyl, piperazinyl and pyrrolidinyl, and
• heterocyclic ring is optionally substituted by one or two substituents independently selected from the group consisting of hydroxyl and C1-C3 alkyl optionally substituted with one or two substituent of hydroxyl or C1-C3 alkoxyl,
• the compound of the invention has Formula (I-P-bc)
• R C1 and R C2 are each independently -CH2-,
• C is -halo(Ci-C5alkyl), unsubstituted -Ci-CsallkyI, or unsubstituted -C2-Csalkenyl-;
• R B1 and R B2 are each independently -CH2-;
• R A2 and R A1 are each independently H, halogen, hydroxyl, -0-P(0)(OH) 2 ,
• Ci-C6alkyl of said optionally substituted (Ci-C6alkyl), or optionally substituted (Ci-C6alkyl)oxy- is optionally substituted with 1-4 substituents each independently selected from the group consisting of hydroxyl, -0-P(0)(OH)2, -0-P(0)(R I R II )2, Ci-C4alkoxyl, -N(R e )(R , -CO 2 (R , optionally substituted phenyl, and optionally substituted 5-6 membered heterocycloalkyi; wherein said optionally substituted phenyl, or 5-6 membered heterocycloalkyi is optionally substituted by 1-4 substituents each independently selected from halogen, hydroxy, -0-P(0)(OH) 2 , -0-P(0)(R I R II )2, amino, (G-CealkyOamino-, (Ci-C6alkyl)(Ci-C6alkyl)amino-,
• each R d is independently H or Ci-C4alkyl
• R e is selected from H, (Ci-C4alkyl), -CO(Ci-C4alkyl), -OCO(G-C4alkyl), -(G-Galkyl)- NH2, -(Ci-C4alkyl) Ci-C4alkoxy, or -C02(G-C4alkyl),
• each R f is H or (Ci-C4alkyl);
• R 6 is H
• R 14 is Ci-dalkyl
• R 15 is G-Oalkyl
• R 16 is Ci-dalkyl
• each occurrence of R 1 and R n are independently (Ci-C6alkyl)oxy-,
• the compound of the invention has Formula (I-bc)
• R C1 and R C2 are each independently -CH2-,
• C is -halo(Ci-C5alkyl), unsubstituted -Ci-Csallkyl, or unsubstituted -C2-C5alkenyl-;
• R B1 and R B2 are each independently -CH2-;
• B is -halo(Ci-C5alkyl), unsubstituted -Ci-Csallkyl, or unsubstituted -C2-C5alkenyl-;
• R A2 and R A1 are each independently H, halogen, hydroxyl,
• Ci-C6alkyl of said optionally substituted (Ci-C6alkyl), or optionally substituted (Ci-C6alkyl)oxy- is optionally substituted with 1-4 substituents each independently selected from the group consisting of hydroxyl, Ci-C4alkoxyl, - N(R e )(R , -C02(Rf), optionally substituted phenyl, and optionally substituted 5- 6 membered heterocycloalkyl; wherein said optionally substituted phenyl, or 5-6 membered heterocycloalkyl is optionally substituted by 1-4 substituents each independently selected from halogen, hydroxy, amino, (G-C6alkyl)amino-, (Ci-C6alkyl)(Ci-C6alkyl)amino-, halo(Ci-C6alkyl), hydroxy-(Ci-C4alkyl)-, halo(Ci-C4alkoxy)-, Ci-C
• each R d is independently H or Ci-C4alkyl
• R e is selected from H, (Ci-C4alkyl), -CO(Ci-C4alkyl), -OCO(Ci-C4alkyl),
• each R f is H or (Ci-C4alkyl);
• R 6 is H; R 14 is optionally substituted Ci-C4alkyl;
• R 15 is G-Galkyl
• R 16 is Ci-dalkyl
• each occurrence of R 1 and R n are independently (Ci-C6alkyl)oxy-,
• each R e is independently selected from H, -(Ci-C4alkyl)-NH2, or -(Ci-C4alkyl) Ci-C4alkoxy and each R f is independently H or
• Representative compounds of this invention include the compounds of the Examples. It will be appreciated that the present invention encompasses compounds of Formula (I-N), Formula (I) and Formula (I-P) as the free base and as salts thereof, for example as a pharmaceutically acceptable salt thereof. In one embodiment the invention relates to compounds of Formula (I-N), Formula (I) and Formula (I-P) in the form of a free base. In another embodiment the invention relates to compounds of Formula (I-N), Formula (I) and Formula (I-P) in the form of a salt, particularly, a pharmaceutically acceptable salt. It will be further appreciated that, in one embodiment, the invention relates to compounds of the Examples in the form of a free base. In another embodiment the invention relates to compounds of the Examples in the form of a salt, particularly, a pharmaceutically acceptable salt.
• the compounds of Formula (I-N), Formula (I) or Formula (I-P) are not the following compounds:
• the compounds of Formula (I-N), Formula (I) or Formula (I-P) are not the following compounds:
• the compounds of Formula (I-N), Formula (I) or Formula (I-P) are not the following compounds:
• the compounds of Formula (I-N), Formula (I) or Formula (I-P) are not the following compounds:
• the compounds of Formula (I-N), Formula (I) or Formula (I-P) are not the following compounds:
• the compounds of Formula (I-N), Formula (I) or Formula (I-P) are not the following compounds:
• the compound of Formula (I-N), Formula (I) or Formula (I-P) is (£5-l-(4-(5-Carbamoyl-2-(l-ethyl-3-methyl-lH-pyrazole-5 arboxamido)-lH-benzo[d]imidazol- l-yl)but-2-en-l-yl)-2-(l-ethyl-3-methyl-lH-pyrazole-5-carboxamido)-7-(3-hydroxypropoxy)-lH- benzo[d]imidazole-5-carboxam
• the compound of Formula (l-N), Formula (I) or Formula (l-P) is
• the compound of Formula (l-N), Formula (I) or Formula (l-P) is
• the compound of Formula (l-N), Formula (I) or Formula (l-P) is
• the compound of Formula (l-N), Formula (I) or Formula (l-P) is
• the compound of Formula (l-N), Formula (I) or Formula (l-P) is or 3-(((Z)-6-carbamoyl-3-((E)-4-((Z)-5-carbamoyl-2-((l-ethyl-3-methyl-lH-pyrazole-5- carbonyl)imino)-7-methoxy-2,3-dihydro-lH-benzo[d]imidazol-l-yl)but-2-en-l-yl)-2-((l-ethyl-3- methyl-lH-pyrazole-5-carbonyl)imino)-2,3-dihydro-lH-benzo[d]imidazol-4-yl)oxy)propyl dihydrogen phosphate
• the compounds of this invention may contain one or more asymmetric centers (also referred to as a chiral center), such as a chiral carbon, or a chiral -SO- moiety.
• asymmetric centers also referred to as a chiral center
• Compounds of this invention containing one or more chiral centers may be present as racemic mixtures, diastereomeric mixtures, enantiomerically enriched mixtures, diastereomerically enriched mixtures, or as enantiomerically or diastereomerically pure individual stereoisomers.
• the stereochemistry of the chiral center present in compounds of this invention is generally represented in the compound names and/or in the chemical structures illustrated herein. Where the stereochemistry of a chiral center present in a compound of this invention, or in any chemical structure illustrated herein, is not specified, the structure is intended to encompass any stereoisomer and all mixtures thereof. Accordingly, the present invention encompasses all isomers of the compounds of Formula (I-N), (I-P) or (I), and salts thereof, whether as individual isomers isolated such as to be substantially free of the other isomer (i.e. pure) or as mixtures (i.e. racemates and racemic mixtures). An individual isomer isolated such as to be substantially free of the other isomer (i.e. pure) may be isolated such that less than 10%, particularly less than about 1%, for example less than about 0.1% of the other isomer is present.
• Individual stereoisomers of a compound of this invention may be resolved (or mixtures of stereoisomers may be enriched) using methods known to those skilled in the art. For example, such resolution may be carried out (1) by formation of diastereoisomeric salts, complexes or other derivatives; (2) by selective reaction with a stereoisomer-specific reagent, for example by enzymatic oxidation or reduction; or (3) by gas-liquid or liquid chromatography in a chiral environment, for example, on a chiral support such as silica with a bound chiral ligand or in the presence of a chiral solvent.
• stereoisomers may be synthesized by asymmetric synthesis using optically active reagents, substrates, catalysts or solvents, or by converting one enantiomer to the other by asymmetric transformation.

Landscapes

• Chemical & Material Sciences (AREA)
• Health & Medical Sciences (AREA)
• Organic Chemistry (AREA)
• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Virology (AREA)
• Molecular Biology (AREA)
• Communicable Diseases (AREA)
• Oncology (AREA)
• Immunology (AREA)
• Engineering & Computer Science (AREA)
• Epidemiology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Biochemistry (AREA)
• Tropical Medicine & Parasitology (AREA)
• AIDS & HIV (AREA)
• Pulmonology (AREA)
• Biotechnology (AREA)
• Microbiology (AREA)
• Mycology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Pyrrole Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Plural Heterocyclic Compounds (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
• Peptides Or Proteins (AREA)
• Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
• Hydrogenated Pyridines (AREA)
• Pyridine Compounds (AREA)
• Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
• Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)

Priority Applications (49)

Applications Claiming Priority (6)

Related Child Applications (3)

Publications (1)

Family

ID=58503675

Family Applications (1)

Country Status (33)

Cited By (107)

Families Citing this family (18)

Citations (82)

Family Cites Families (23)

• 2017
  • 2017-04-05 ES ES17716312T patent/ES2921855T3/es active Active
  • 2017-04-05 UA UAA201810983A patent/UA123407C2/uk unknown
  • 2017-04-05 KR KR1020187032396A patent/KR102527784B1/ko active Active
  • 2017-04-05 CA CA3019630A patent/CA3019630A1/en active Pending
  • 2017-04-05 EP EP22159533.3A patent/EP4032885A1/en active Pending
  • 2017-04-05 SI SI201731184T patent/SI3440076T1/sl unknown
  • 2017-04-05 CN CN201811311714.9A patent/CN109608443B/zh active Active
  • 2017-04-05 DK DK17716312.8T patent/DK3440076T3/da active
  • 2017-04-05 PT PT177163128T patent/PT3440076T/pt unknown
  • 2017-04-05 PL PL17716312.8T patent/PL3440076T3/pl unknown
  • 2017-04-05 IL IL295649A patent/IL295649B1/en unknown
  • 2017-04-05 RS RS20220734A patent/RS63462B1/sr unknown
  • 2017-04-05 US US16/091,189 patent/US10981901B1/en active Active
  • 2017-04-05 LT LTEPPCT/IB2017/051945T patent/LT3440076T/lt unknown
  • 2017-04-05 SG SG10201900628RA patent/SG10201900628RA/en unknown
  • 2017-04-05 CR CR20200045A patent/CR20200045A/es unknown
  • 2017-04-05 JO JOP/2017/0083A patent/JOP20170083B1/ar active
  • 2017-04-05 CN CN202110799242.1A patent/CN113549110B/zh active Active
  • 2017-04-05 PE PE2018002003A patent/PE20181919A1/es unknown
  • 2017-04-05 MX MX2020009948A patent/MX387353B/es unknown
  • 2017-04-05 MX MX2020009947A patent/MX387354B/es unknown
  • 2017-04-05 CN CN201780022379.8A patent/CN109071514B/zh active Active
  • 2017-04-05 PE PE2018001834A patent/PE20181884A1/es unknown
  • 2017-04-05 PE PE2018002322A patent/PE20181920A1/es unknown
  • 2017-04-05 MX MX2018012333A patent/MX379169B/es unknown
  • 2017-04-05 NZ NZ745957A patent/NZ745957A/en unknown
  • 2017-04-05 EP EP17716312.8A patent/EP3440076B1/en active Active
  • 2017-04-05 KR KR1020187031915A patent/KR102527786B1/ko active Active
  • 2017-04-05 SG SG10201900629VA patent/SG10201900629VA/en unknown
  • 2017-04-05 SG SG11201808621TA patent/SG11201808621TA/en unknown
  • 2017-04-05 AU AU2017247798A patent/AU2017247798C1/en active Active
  • 2017-04-05 JP JP2018552758A patent/JP6746712B2/ja active Active
  • 2017-04-05 HU HUE17716312A patent/HUE058932T2/hu unknown
  • 2017-04-05 MY MYPI2018703686A patent/MY189100A/en unknown
  • 2017-04-05 SM SM20220339T patent/SMT202200339T1/it unknown
  • 2017-04-05 WO PCT/IB2017/051945 patent/WO2017175147A1/en not_active Ceased
  • 2017-04-05 HR HRP20220936TT patent/HRP20220936T1/hr unknown
  • 2017-04-05 CR CR20200044A patent/CR20200044A/es unknown
  • 2017-04-05 UY UY0001037195A patent/UY37195A/es unknown
  • 2017-04-05 IL IL285702A patent/IL285702B/en unknown
  • 2017-04-06 TW TW107147613A patent/TWI777014B/zh active
  • 2017-04-06 TW TW111130004A patent/TWI868471B/zh active
  • 2017-04-06 TW TW106111324A patent/TWI776806B/zh active
• 2018
  • 2018-01-03 US US15/730,664 patent/US10189820B2/en active Active
  • 2018-08-30 IL IL261482A patent/IL261482B/en unknown
  • 2018-09-06 IL IL261657A patent/IL261657B/en unknown
  • 2018-09-13 AU AU2018229497A patent/AU2018229497C1/en active Active
  • 2018-09-13 AU AU2018229498A patent/AU2018229498C1/en active Active
  • 2018-10-04 DO DO2018000217A patent/DOP2018000217A/es unknown
  • 2018-10-04 CO CONC2018/0010727A patent/CO2018010727A2/es unknown
  • 2018-10-05 PH PH12018502151A patent/PH12018502151B1/en unknown
  • 2018-10-05 CL CL2018002850A patent/CL2018002850A1/es unknown
  • 2018-10-11 PH PH12018502179A patent/PH12018502179A1/en unknown
  • 2018-10-15 PH PH12018502202A patent/PH12018502202A1/en unknown
  • 2018-11-20 CL CL2018003291A patent/CL2018003291A1/es unknown
  • 2018-11-20 CL CL2018003290A patent/CL2018003290A1/es unknown
• 2020
  • 2020-01-30 DO DO2020000019A patent/DOP2020000019A/es unknown
  • 2020-01-30 AU AU2020200692A patent/AU2020200692C1/en active Active
  • 2020-01-30 DO DO2020000018A patent/DOP2020000018A/es unknown
  • 2020-02-26 JP JP2020030908A patent/JP6861307B2/ja active Active
• 2021
  • 2021-01-25 US US17/156,893 patent/US11365190B2/en active Active
  • 2021-03-26 JP JP2021054203A patent/JP7119158B2/ja active Active
• 2022
  • 2022-05-17 US US17/663,749 patent/US11970480B2/en active Active
  • 2022-08-01 JP JP2022122895A patent/JP7466596B2/ja active Active

Patent Citations (101)